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CHAPTER 1 - INTRODUCTION
The topic of this dissertation covers the study of acute cell injury phenomenon.
During my appointed schedule in an Emergency Room as a physician, I have faced and
treated many acute injuries which manifest in the form of stroke, myocardial infarction,
or acute kidney failure in patients.

Acute injuries have clearly identifiable damage

mechanisms, as opposed to chronic injuries like Alzheimer’s or Parkinson’s diseases,
where the cause of the disease is essentially unknown. In most of the cases, we could
sustain the life of the patients. However, we could not prevent the progression of tissue
death after acute injuries. These clinical conditions that we mentioned have resisted
many attempts at therapies. The overall failures of therapies to prevent cell death
brings our lab to develop a new approach to acute cell injury in the form of a
mathematical theory.

This theory derived from the research of acute cell injury,

particularly in brain ischemia and reperfusion (I/R) presented in the mathematical
model. We abstract cell injury to consist of the action of two variables D and S. We
define variable D as the total damage caused by the injury, and variable S as the total
induced stress response. My goal in this Dissertation is to undertake the very first
attempt to estimate the variables D and S. Moreover, we will evaluate the goodness of
fit of the theory based on the D and S measurements from the experiments. We use
the rat model of the global brain I/R to test the estimated measurements of D and S.
This Dissertation will explore the background of the brain I/R reviewing the failure
of many efforts in stopping the cell death process after brain I/R, known as
neuroprotection. Next, I will present the theory, and then propose my hypotheses. I will
provide the three Aims of the project: (1) To estimate D by levels of protein aggregation
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after brain I/R, (2) to estimate S by changes in mRNA levels on polysomes after brain
I/R, and (3) That the estimates of D and S can be fit by the math theory of acute cell
injury.

I will present experimental designs, and methods in every aims and result.

Finally, this dissertation will end with the discussion of how well the data in the
experiment fit the proposed theory, the limitations of this work, and future directions.
1.1 Brain Ischemia and Reperfusion
Ischemia is a condition where the tissue has low or no blood flow resulting in a
reduced level of oxygen and glucose in the tissue. After the ischemia, the return of
normal blood flow to the tissue is called reperfusion.

In the brain, two forms of

pathological ischemia are known as global and focal brain ischemia. Ischemia in the
whole brain is known as global brain ischemia, which may result from the consequence
of cardiac arrest event. On the other hand, stroke or focal brain ischemia happens
when there is an occlusion of the artery as a cause of an emboli or rupture in the artery.
Stroke, cardiac arrest, and resuscitation have a high incidence from the brain I/R
manifestation. In the United States, around 1,200,000 people are suffered from stroke
every year. Stroke causes 20% mortality and 80% morbidity1. However, cardiac arrests
occur in 750,000 individuals in the United States annually2. The latter causes a higher
mortality rate of 80%, which most of the mortality (50-70%) is related to the brain
damage3. Both conditions create not only enormous financial burden including health
care and research costs, but also social costs including loss of economic productivity,
disruption of families and suffering of people.

For instance, the cost of stroke is

estimated to be 50 billion US dollars per year in both of financial and social costs4.
However, brain I/R research has shown a partial success in controlling hypertension
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and obesity, as its risk factors. The number of stroke and cardiac arrest events have
reduced over the past years5. To date, there are only a few treatments for patients with
stroke or cardiac arrest. We will discuss in this chapter the mechanism of the brain I/R
and the failure of neuroprotection as the treatment option. The therapies aim to stop
neuronal death as the brain I/R outcome. The theory of acute cell injury gives new
insights, not only about the nature of cell death, but also related to the failing of
neuroprotection.
1.1.1 Brain I/R damage
Brain I/R causes two forms of neuronal death known as necrosis and delayed
neuronal death (DND)6-12. In a prolonged stroke which lasts around six to eight hours or
cardiac arrest which is happening for more than 30 minutes, necrosis of brain tissue
occurs13-15. However, there is no neuronal death in a shorter brain I/R duration mainly
after ~15 minutes of stroke or 3-5 minutes of cardiac arrest. When short insults are
happening in the brain, it will serve as protection to the brain from the longer insults.
This situation is known as ischemic preconditioning or ischemic tolerance16-18. If the
duration of the brain I/R is moderate, the cell takes a longer time to die, after reperfusion
has initiated, and this is the DND. In this case, neuronal death appears in hours or days
after the ischemic insults15, 19. In a rat model, CA1 type neurons in hippocampus die 72
hours after 10 minutes of global brain ischemic insult, while another neuronal type in the
same brain region known as CA3 neurons survive20-22. We used this rat brain I/R model
in this Dissertation, as described below. Ischemic stroke is of two types. Transient
stroke has ischemia followed by reperfusion. A permanent stroke may occur in the case
of no reperfusion. However, both temporary and permanent stroke develop a necrotic
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core in the brain tissue. The tissue around the core, termed as penumbra, will die by
DND mechanism long after the ischemic insult. This process could variably appear in
days, weeks or months and ends with a wider lesion. The neurological deficits driven
by this process are usually severe23-28. Currently, it is still not understood why DND
process occurs after brain I/R. The theory proposed in this Dissertation suggests a new
explanation of DND to be caused by injury dynamics and not molecular pathways.
1.1.2 Molecular mechanisms
There are a lot of detailed researches of cell and molecular events in brain
ischemia field. Searching the term “cerebral ischemia” as a keyword provides 124,064
citations by August 15, 2017, in PubMed. Neurons revealed many molecular changes
after brain ischemia, a situation called as “multifactorial” injury process. The term of
“multifactorial” is also used for explaining another form of acute cell injury, particularly
trauma and poisoning. Since much is known about brain changes after an ischemic
insult, here I will only review the major pathways activated in brain after I/R.

The

pathways inaugurate with the loss of ATP. Since ATP has main job of setting ion
gradients in neurons, loss of ATP in ischemia is followed by the equilibration of ion
between neurons and extracellular space. This process also includes the changes in
tonicity, ion activity, and pH inside of neurons. With reperfusion, oxygen and glucose
return to altered brain cells and cause free radicals activation (also called reactive
oxygen species, ROS) and many other forms of damage.

However, some known

ischemia activated molecular changes protect the neurons, including the unfolded
protein response and heat shock response to safeguard the protein from further
damage. Antioxidant response is also played a role in protecting the neurons5. The
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protective pathways are generally called stress responses.
The major consequence of global brain ischemia is the loss blood flow. As a
result, there will be no transport of glucose or oxygen to the cell. The main effect then is
rapids loss of ATP in brain cells.

It is reported that ATP concentration in brain

deteriorate promptly to zero after 7 minutes of ischemia29. Subsequently, it stops all
ATP- dependent metabolic processes. For the neuron, the primary ATP-dependent
function is to maintain the ion gradients between inside and outside of the cell10.
Furthermore, the loss of energy causes the inhibition of Na+-K+ ATPase and Ca2+ATPases which cause the movement of ions down to concentration gradients. The
substantial concentration ratio caused by Ca2+ is 10,000:130, from extracellular to the
cytoplasm. The large influx of Ca2+ is the primary damaging agent inside the neuron. If
ischemia exists over an extended period of time, equilibrate Na+ and K+ ions also
equilibrate and develop a net water influx. The outcome of this event will end to a
neuronal membrane lysis which will leads to immediate neuronal death called necrosis
(Figure 1).
For moderate ischemia times, Ca2+ influx results in additional significant
damages. It leads to various enzymes activations including calpain proteases,
phospholipases, and DNAses that degrade proteins31,

32

, lipids33, and DNA34,

respectively. Degradation of lipids leads to altered cell membrane properties and to
arachidonic acid accumulation that can make prostaglandins33.

Ca2+ induces nitric

oxide (NO) synthases activation that will result in vessels vasodilatation. However, an
excess concentration of NO will cause free radical damage35. On the other hand, during
the loss of blood flow, the production of ATP will shift to glycolysis that produces excess
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lactic acid in brain tissue that contributes to a further damage by altering pH of cells36.
Reperfusion following the brain ischemia will result in returning of the oxygen and
glucose to the cell. In about ten to thirty minutes of reperfusion, mitochondria will return
to oxidative synthesis of ATP12. However, oxygen re-exposure is destructive due to the
free radical ROS production which will compound the previous damage from
ischemia12,37,38. Various ROS has been detected after brain I/R including nitric oxide,
peroxidized lipids39, mitochondrial ROS40, and others from water12. The free radicals
can impair the whole cell apparatus functions such as membranes, proteins, DNA, and
RNA. Figure 1 summarizes major pathways of ischemia, the “ischemic cascade”.

Ischemia
loss of ATP

ion equilibration: Ca2+, Na+, K+
ATP‐dependent processes stop
lipolysis, proteolysis, nucleolysis

Reperfusion
protein misfolding

Gene Expression

Cell Damage
free radicals:
lipid peroxidation
protein peroxidation
NO & peroxynitrite

mitochondria
dysfunction

ER stress

cytoplasmic
edema

intrinsic
apoptosis

necrosis

DNA fragmentation

heat
shock
response

anti‐oxidant genes
DNA repair

unfolded
protein
response

others…

Figure 1: Ischemic “Cascade”
Other numerous changes have been identified after brain I/R. Some examples
include apoptotic pathways activation such as caspase 341-43 and mitochondrial protein
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Bcl and Bax44-46. It is also reported there are swelling of endoplasmic reticulum and
Golgi apparatus47-49, shrinkage of cell nucleus7, 50, 51, the disintegration of cytoskeleton
structure52, dissociation of neuronal polysomes and inhibition of protein synthesis53-55,
as well as loss of mitochondrial fission and fusion function56,57. All of these changes
have their individual time course.

The activation of each pathway depends on the

length of ischemia, as well as the type of neurons studied. In addition, it sometimes
depends on which type of species is considered. In most of the cases, it is still unknown
whether the change is due to a physiologic reaction to ischemia, or is a form of cell
damage.
Various genes changes occur after brain I/R.
hundreds
process

58-65

to

Based on microarray studies,

thousands of genes undergo up-regulation and downregulation

. Similar to the damage, many factors are affecting the changes of the

genes. Many genes are activated as a cell stress responses including heat shock66-70,
unfolded protein response (UPR)71-76 , anti-oxidant genes77-80, NF-kB pathway81, 82, DNA
repair pathways34, 83-86, and pro-anabolic pathways like PPAR gamma87-90, to help cells
recover after I/R damage.
DND was thought to be the same as apoptosis. However, DND and apoptosis
have distinct appearance morphologically7, 50, 51. Among all of the enzymes, caspases,
the main proteins involve in apoptosis, are only one of the thousands of molecular
changes in neurons after brain I/R. Inhibitors of apoptosis can stop neuronal death in
some animal models of brain I/R but do not alter the outcome in the human brain I/R91.
All changes listed above are thought to make the “ischemic cascade” (Figure 1).
This idea of the cascade is like dominoes, one hitting the next, to eventually cause a cell
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death event such as apoptosis or necrosis. Almost all clinical trials of neuroprotection
were performed based on the attempt to inhibit one of the pathways in the ischemic
cascade. However, if brain I/R causes a cascade, a drug should stop the cascade at
some point in the diagram and prevent cell death. Below I will summarize how every
clinical trial which is developed based on ischemic cascade failed in improving the
outcome in humans.
1.2 Failure of Neuroprotection after Brain Ischemia
As previously described, neuroprotection targets to stop ischemic cascade at
some point in the cell death pathways. By 2006, there were 114 drugs tested in stroke
clinical trials to achieve neuroprotection. Of all of those 114 clinical trials, they all failed.
This failure was summarized by O’Collins et al. in 200691. This section gives summary
of O’Collins et al. paper.
The paper gives a three-page table to classify drugs tested in categories:
excitotoxicity,

anti-inflammatory,

antioxidant,

anti-apoptotic/regeneration,

calcium/adrenergic/hypertensive agents, thrombolytic, nootropic, fluid regulation,
oxygen delivery, and other. Each category consists many drugs which were thought to
work in a pathway in ischemic cascade to stop progression to cell death. In conclusion,
the authors state “no relationship was found between mechanism and efficacy” for
drugs tested. Also very important to this Dissertation, the authors say:
“No particular drug mechanism distinguished itself on the basis of superior
efficacy in animal models of focal ischemia. This may reflect the multifaceted
nature of the sequelae of ischemic stroke and suggest a role for combination
therapy to target multiple processes. Alternately, it might suggest that our
conception of stroke needs reformulation. A tendency to exclusively frame drug
activity in terms of the dominant schema of stroke damage (eg. excitotoxicity,
free radical damage), coupled with the sometimes arbitrary attribution of a drug
mechanism to one of several nonmutually exclusive groupings, might distract
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from other paradigms with greater explanatory power, thus hindering the
development of more effective treatments.”
This quote is essential for this Dissertation. It says that a new way to study cell
injury might be critical to overcoming the failure of neuroprotection. This Dissertation will
consider a new “paradigm” of cell injury. I will discuss how it has a “greater explanatory
power” to explain (1) the cause of cell death, and (2) how to make neuroprotection
function properly.
1.3 General Theory of Acute Cell Injury
Drs. DeGracia, ZF Huang, and S. Huang formulated the nonlinear dynamical
theory of acute cell injury in 201292. The theory is shown by presenting two nonlinear
ordinary differential equation (ODE) systems:
 nD
dD
 vD n
 kD D
dt
D  S n
n
dS
 vS n S n  k S S
dt
S  D

(1)

The theory described how the total damage, D, and total induced stress
response, S, change as a function of time and of parameters v, k, , and n. This theory
can be easily explained by understanding four postulates:
1.

D and S form a network of damage and protective influences.

2.

The dynamics of D and S formation rate follow Hill functions.

3.

D and S are exponentially driven by I and –I, respectively.

4.

Decay from the attractor state, (D*, S*), is a function of |D* -S* |.

The four are explained below. There are additional two more postulates which
will be explained in Chapter 4 but introduced now:
5.

The velocity parameter v is constant equal to 1.
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6.

The decay parameter k is constant equal to 1.

1.3.1 D and S form a network of damage and protective influences
From previous research on brain I/R reviewed above, it showed some changes
caused by ischemia damage the brain cells, but others protect neurons. Damage is to
be thought of as non-physiological molecules in the cell, or of physiological molecules
outside normal concentration ranges. For example, free radical damage to proteins is
not common in healthy neurons37, 40, 93. Ca2+ ion has a low concentration (10-9 M) in the
cytoplasm under normal condition, but in ischemia increases to hundreds of
micromolar94-98. Many damages occur in the brain I/R. All taken together is defined as
D, total induced damage.
Protective changes caused by stress response pathways are programmed in
cellular genes. Some examples involve heat shock response to refold unfolded proteins
in cytoplasm53.

Unfolded protein response protects against unfolded proteins in

endoplasmic reticulum72.

Transcription factor NrF2 activates genes for enzymes to

eliminate ROS, for example peroxidases and glutathione metabolism99.

Some

protection responses present in cell do not require gene activation. Taurine system
uses anion channels to extrude taurine to keep isotonic condition in cell when under
hypertonic conditions of ischemia100-102. Similar to D, all protective changes add
together give S, the total induced stress response.
As stated, D and S defines all damaging and protective influences after acute
injury. One more important feature of D and S is how it considers the many changes of
D and S in making a network of pro-death and pro-survival forces.

For example,

peroxidase enzyme can eliminate reactive oxygen species (ROS) from the cell.
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However, ROS can interact with the peroxidase enzyme and cause free radical damage
to inhibit protein function. The ROS may come from pathway of iron called Fenton
reaction93, 103, 104:
Fe2+ + H2O2 ----> Fe3+ + .OH + OHThis reaction shows separate pathways, protein denaturation, and ROS reaction,
to interact.

Many examples of pathways interacting with each other can also be

considered. Pathways are not distinct from each other but form network of interactions.
In brain I/R acute cell injury, the network influences are of two types only: to
destroy cell (D) or to protect cell (S). Then we add all destructive influences and add all
protective forces and determine the greater. The acute theory of cell injury states when
harmful impacts are higher than protective (D > S), the cell will die. If protective
influences greater than destructive damage (S > D) then the cell will live.
We cannot know all interactions of all pathways. The theory simplifies these
situations, so we only know how D and S change in time. However, we need always to
understand these terms refer to a complex network of molecular pathway interactions.
1.3.2 The dynamics of D and S and Hill functions
We simplify pathway complexity by following totals, D and S to change in time,
called dynamics. Dynamics are to be studied using ODEs of D and S change in time.
The theory makes formation rates of D and S follow S-shaped curves. S-shaped curves
give the threshold parameter, , where effect is 50%. We do not know  beforehand,
but assume there is the threshold amount of D, D, to inhibit S by 50%. There is also a
threshold amount of S, S, to inhibit D by 50%. Then the rate of formation equal to Hill
functions that give S-shaped curves:
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 nD
dD
 vD n
dt
D  S n
n
dS
 vS n S n
dt
S  D

(2)

Parameter n is Hill coefficient, typically called “cooperativity” for example in
hemoglobin O2 binding curve. Parameter n tells how strong the interaction is. In the
cell injury theory, n is measure of how strong is the pathways interaction in a network.
The v parameters are the velocity of formation of D and S. Above in postulate 5 this was
said as vD = vS = 1. Making v a constant is, as mentioned, a problem, but is simplifying
assumption for now.
Eq. (2) is not correct, giving only the rate of formation of D and S. There must be
the rate of decay also so final ODE is net rate = rate of formation minus rate of decay.
The theory gives rate of decay as exponential, like radioactive decay equation with
decay constant k. As with v, the starting assumption is kD = kS = 1. This gives overall
theory of acute cell injury.
n
dD
 vD n D n  k D D
dt
D  S
n
dS
 vS n S n  k S S
dt
S  D

(3)

Postulates 5 and 6 make v and k parameters equal 1. Eq. (3) then is:
n
dD
 n D n D
dt  D  S
n
dS
 n S n S
dt  S  D

(4)

Eq. (4) gives nonlinear dynamics of D and S network of influences and describes
time progression of acute cell injury.
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1.3.3 D and S are exponentially driven by I and –I, respectively
Eq. (4) is not the final theory because injury intensity, I, is not included. When
acute injury occurs there is an injury mechanism that can have variable amount or
intensity.

This may be a force for trauma, concentration for poison, or duration of

ischemia. The amount, or intensity, of acute injury mechanism is parameter, I.
It makes sense that bigger I will give greater D. If the acute injury is stronger,
there will be more damage in the cell. Therefore, I is proportional to D. But what about
S? S, cell protection, will increase as I increase, except because most of the pathways
of S are involving enzymes, we suggest that they will saturate at some amount of I. S is
to be considered similarly as how glucose enters urine due to the saturation of glucose
transporters, in diabetes. We define that S saturate with damage, D. After saturation of
S, I increase, but S would decrease because excess D would destroy S, as with
example of ROS damaging peroxidase from above. For S, as I increase, first S
increases but then decreases.
We cannot change D and S by I because D and S change by time, t, in Eq. (4).
The theory makes threshold parameters change by I:
D  eI
S  e I

(5)

There are two reasons to assume an exponential function: (1) exponential
phenomenon is ubiquitous in nature, and (2) the expressions in Eq. (5) fit how D and S
change with I explained above. However, there is one problem. When I = 0, Eq. (5) = 1,
to mean D and S exist when injury intensity, I, is zero. The correction is to also multiply
Eq. (5) by I:
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 D  Ie I
 S  Ie  I

(6)

Therefore, to make proportions to equality, we add constants of proportionality to
give Eq. (7)
 D  cD Ie I D
 S  cS Ie  I S

(7)

The new parameters cD and cS are multiplying constants. The D and S are
exponential constants like decay constants. The general form of Eq. (7) is illustrated by
Figure 2. This graph depicted the value of D increase will always corresponds with I
but that S first increase, then decrease with I increase. Eq. (7) is the main assumption
of acute cell injury theory that thresholds of D and S change with injury intensity I.
The final theory of acute cell injury is attained when Eq. (7) is applied into Eq. (4)
to give:
dD
(cD Ie I D ) n

D
dt (cD Ie I D ) n  S n
(cS Ie  I S ) n
dS

S
dt (cS Ie  I S ) n  D n

(8)

Figure 2: Plots of Eq. (7). D (red) and S
(green). Parameters are: cD = 0.1, cS = 20, D
= 0.1, S = 0.9.
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1.3.4 Decay from the attractor state, (D*, S*), is a function of |D* -S*|
The last postulate is complicated in explanation, coming from the study of
answers to Eq. (8). Eq. (8) gives time courses that end at final points of D and S called
“attractor states”. Attractors are written (D*, S*). At attractors, D and S rate of change
equals zero. The system is “frozen” forever at (D*, S*).
In real biological acute injury, when the cell does not have the injury before
applying an acute injury, then D = S = 0.

Once system is injured, D and S both

increase, but then two cases only are possible. First case, cell may recover from injury,
which is to heal. Then the system is back to the uninjured state where D = S = 0.
Alternatively, second case, where injury may be very intense (I is high) that force cells
to die. In this case, also, D = S = 0 because cell dies and has no variables. In real injury
the cell begins and ends at D = S = 0, whether lives or dies. But answers to Eq. (8)
always end at values (D *, S*) and these can be any number but not zero.
A “bandage” was utilized to Eq. (8) to fit actual biological injury and is postulate 4.
Instead of cell ending at (D*, S*) and staying forever at this point, postulate 4 makes cell
at (D*, S*) for only one instant then begins to decay back to D = S = 0, or point (0, 0).
Postulate 4 states decay is exponential from (D*, S*) to (0, 0) and how fast, the rate, cell
goes is determined by the value of D* -S* not including sign, is absolute value |D* -S*|.
Below is the equation:

dD
  | D * S* | D
dt
dS
  | D * S* | S
dt

(9)

Figure 3 shows final theory where two different ODE systems, Eqs. (8) and (9)
are “glued” together. From Figure 3, there are two critical points to mention. One, why
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use |D* -S* | to determine rate from attractor to (0,0)? Two, “gluing” two ODE systems
is artificial “bandage” in theory, but it is crucial for the outcome of proposed
experiments, which will be more reasonable after discussing why |D* -S* |?

Figure 3: Theory of acute cell injury is two ODE systems called “uphill” and
“downhill”.
We call the answer to Eq. (8) “uphill” because cell goes from (D, S) = (0, 0) to (D,
S) = (D*, S*). “Uphill” is an analogy for kicking ball up a hill that goes to a maximum
point before rolling back down the hill105. This is a valuable lesson by saying Eq. (8)
gives maximum deviation of injured system from the control state. This is very crucial to
understand by saying any injury, intensity of I, will cause a maximum deviation away
from control state. However, the cell then must either recover or die.
When thinking about meaning of D* and S*, one of these is the maximum away
from control. If D* > S*, then D* is maximum D, and the cell will die. However, when S*
> D*, S* is maximum S away from control and stress responses can eliminate damage.
Values of D* and S* tell if cell lives or dies by D* >*S cell dies, S* > D* cell lives. This is
the most important, as from attractor answer to Eq. (8) we can tell if cell lives or dies.
Therefore, the cause of death is due to injury dynamics, not pathways.
Attractor also tells how fast cell recovers or dies. If D* is very big compared to S*,

17
then lots of damage is happening in the cell. As a result, the cell will die fast. If S* is
very big compared to D*, which means stress responses is hugely greater than the total
damage, the cell recovers fast. But if D* is only slightly bigger than S*, then it takes long
time for them to “battle” before D wins. Also, when S* slightly larger than D* it takes
longer for S to win over D. Subtracting D* and S* to get |D* -S* | tells how fast or slow
“downhill” time course goes.
This is a very important understanding from Eq. (8) plus Eq. (9) because in
ischemia there is necrosis as well as DND. In spite of much searching, no “definitive”
pathway explanation for DND has been discovered. The theory of cell injury defines
why there is DND, because D* only slightly larger than S* at maximum deviation from
the control state. This is a prediction of the theory that it is very important to explain that
DND is not a result from a molecular pathway or cascade, but is an outcome of injury
dynamics. It also is a specific prediction to test the theory.
An artificial gluing of two ODE systems infers another two important ideas about
understanding the theory of acute cell injury. Most important for this Dissertation, we
wonder if we can make ODE equations that start at (0, 0) and also end at (0, 0) without
artificial “gluing” of two different ODE systems. In Chapter 4 we return to this question
and show a new form of the acute cell injury model that does not require artificially
gluing two ODE systems together.
1.3.5 Neuroprotection and nonlinear theory of acute cell injury
Here I discuss how theory gives new understanding of neuroprotection.

As

described above, ODE system gives time courses as answers. However, there is more
common answer to ODE systems which is called phase plane that contains all
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trajectories for a set of input parameters (I, cD, D, cS, S, n). It is discovered that all
trajectories end at same point of phase plane, called attractor state. If parameters
change, so does attractor points. If one parameter is caused to vary, then a series of
phase planes is used to construct a bifurcation diagram. The bifurcation diagram plots
attractor point values versus the changing parameter, called control parameter. The
bifurcation diagram gives more general study of ODE system than single trajectories.
The control parameter to vary in the theory is injury intensity, I.

Other

parameters, (cD, cS, D, S, n) are set to be constant and I is changed over range Imin to
Imax. This is to use theory to explain, for example, 1 min ischemia, 2 min ischemia, up
to 20 min.

Changing I is applying different strengths of injury intensity to system.

Parameters (cD, D) are symbols for the damage agent, such as ischemia, trauma,
poison, etc. Parameters (cS, S) are to indicate the cell type that is injured.
In the 2012 paper, DeGracia et al show (1) there are only two types of phase
planes, and (2) there are only four types of bifurcation curves. The two types of phase
planes are called monostable, when there is one attractor, and bistable, when there are
two attractors and one repeller, shown in Figure 4. The four types of bifurcation
diagrams are labeled as (1) monostable, (2) type A bistable, (3) type B bistable, and (4)
double bistable.
Figure 4 depicts on how to make a type A bistable bifurcation diagram from
series of phase planes by changing the parameter I. It is seen for I = 1 and 2, phase
plane is monostable with attractor S* > D* so cell survives. At I = 4.5 and 5, is also
monostable but D* > S* and cell dies. For I = 3 and 3.9, phase plane has two attractors
and one repeller (blue point). It is called “bifurcation” from I = 2 to I = 3, and bifurcation
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again from I = 3.9 to I =4.5. Bifurcation is when attractor goes from monostable to
bistable or bistable to monostable. Taking value of D* plotted vs. I gives graph in Figure
4B, is bifurcation diagram of D* vs I. Area marked with gray is a bistable region of ODE
answer. Bistable answers give new explanation of therapy as now explained.
The theory proposed a new paradigm of neuroprotection.

First, we can say

precisely that a cell will die when D* > S*. However, illustrated in Figure 4, when
system is bistable, some values of I with D* > S* have the possibility to survive (in gray
region). Bistability is the new paradigm of neuroprotection. A cell fated to die can only
be caused to survive if it is in bistable region. We now express this precisely using
math.
We use theory to make equation to calculate tipping point injury, IX. When D =

S, death and survival influences exactly equal and this is tipping point, IX. We solve this
equation for I.

cD IeI D  cS Ie I S
To get IX tipping point value of I.

Ix 

ln cS  ln cD
D  S

(10)

For above example in Figure 4, IX is calculated by parameters listed at bottom of
Figure 4B.
Ix 

ln(2.5)  ln(0.1)
 3.22
0.1  0.9

For I < 3.22, cell survives injury because S* > D*. For I > 3.22, cell dies because
D* > S*. But because bistable attractors, is not so simple. From I =3.22 to ~I = 4,
system is bistable and could either live or die because both D* > S* and S* > D*
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attractor is answer to ODE system. This means system injured by I values from 3.22 to
~4 could possibly live. These ODE answers indicate that therapy is only possible when
injured system is bistable. For I > ~4, there is only attractor with D* >S*, and cell will die
always because no survival attractor is in ODE answer.
Figure
4:
Bifurcation
diagram made from series
of phase planes varying
parameter I. Figure from 92

We think this is the most important conclusion from the theory that therapy is only
possible when injury is bistable in dynamics. This is the most important prediction of
theory. We would like to prove if this prediction is true or not. But to prove this
prediction, we must measure D and S time courses. Therefore, the purpose of My
Dissertation is to test whether it is possible to measure D and S time courses.
1.4 Hypotheses and Aims
As mentioned above, the nonlinear dynamic theory of acute cell injury proposed
new understandings. First, if D* > S* after an injury, the injured cell will die. The theory
tells us the cell dies not because of some specific set of molecular pathways, but
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because of injury dynamics. Second is the prediction that therapy is only possible when
there are bistable dynamics. These important predictions of theory need to be tested by
measuring the theory. The key measurements are to measure how total damage, D,
and total stress response, S, change in time. However, D and S are new ideas to this
theory and never previously measured. This Dissertation will test if it is possible to
measure D and S by proposing the three Aims of this Dissertation.
Aim 1: D can be quantitatively estimated by levels of protein aggregates
Hypothesis: As described previously, several damages happened in neurons
after brain I/R, including free radicals, acidosis, ions concentration changes, an
alteration in redox reaction, proteolysis, amongst others. In the theory, D is the total of
all damages to the cell. Many of these damages result in denaturation of proteins. The
laboratory of Dr. Bingren Hu reported an accumulation of protein aggregates (PA) in
neurons after brain I/R106, 107. PAs are denatured proteins coated with ubiquitin. PAs are
found inside neurons after brain I/R and in hippocampal CA1 persist until death by
DND106,

108, 109

. PAs also form in neurons that survive, like hippocampal CA3 brain

region, but then disappear at long reperfusion time, and CA3 survives108. I hypothesize
that PAs can be a marker of how D changes in time because many damage pathways
converge to cause proteins to denature after brain I/R. I will measure PAs changing in
time by Western blot for ubiquitinated proteins and quantify with densitometry.
Aim 2: S can be estimated by changes in mRNAs on ribosomes
Hypothesis: It is assumed that the target of changes in genes is to protect the
cell. Then, the gene changes may allow us to track or estimate the variable S.
However; it is also known that when mRNA changes, the protein is not always
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translated. When mRNA is on ribosomes, it is more likely to be translated than when not
on ribosome. Therefore, it is hypothesized that mRNA on ribosomes is one way to
estimate S.

I will measure mRNA on ribosomes by isolating ribosomes, extracting

mRNA and using microarrays to measure mRNAs. I will then compare the result by also
isolating the total mRNA.
For both Aim 1 and Aim 2, I will measure time courses in hippocampal brain
region CA1 that dies and CA3 that survives after brain I/R, as given in the next chapter.
Aim 3: D and S measured time courses fit theory time courses
Hypothesis: How do we know the measurements above are a good way to
estimate D and S change in time? The Aims 1 and 2 will measure time courses. The
time courses should be fit to the D and S time courses generated by the theory of acute
cell injury. The measured time courses of D and S are to be fit to the ODE time courses
using the Nelder-Mead simplex method. Nelder-Mead is a way to fit nonlinear data to
ODE time courses, used in engineering and physics110. Two parts to this Aim 3 are
necessary. First, to learn how to fit all measured data to ODEs because the theory is
new. There are many parameters in Eq. (8). It is to be studied which are the best
parameters to make sense of brain I/R. Second, there may be the case the measured D
and S time courses do not fit Eq. (8). Then it is to ask: can Eq. (8) be modified so it will
give the better fit to measured time courses? This is the method of physics to have
equations, then collect data and if needed to modify equations to provide a better fit of
data.
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CHAPTER 2 - PROTEIN AGGREGATES AS ESTIMATORS OF D
2.1 Introduction
Based on the theory developed by DeGracia et al (2012)92, an acute injury of
intensity, I, damages the cell but also activated genetic stress responses. Total damage,
D, and total stress responses, S, change with time based on a mutual inhibition given by
the theory equations.

This is a “winner take all” model where if D dominates, the

system dies, and if S dominates, the system survives.
Since D is total damage, a possible measure of D is protein aggregates (PA).
PAs are damaged, denatured, or misfolded intracellular proteins in neurons caused by
ischemia (Liu et al., 2005). Many changes in brain I/R could be made to denature
proteins. Proteins need proper pH and ions and redox to maintain correct folded state.
Proteins also need chaperones to fold correctly and chaperones need ATP. Brain I/R
causes loss of ATP, acidosis, changed ion conditions, and changes in oxidationreduction of the cell. The PAs could be good measure of D because many separate
damage pathways cause together the final PAs. This is why it is proposed to measure
PA to estimate D.
We hypothesized that D could be estimated by measuring the change of PAs
over time in an animal model of global brain ischemia, which mimics brain damage after
cardiac arrest and resuscitation. Damaged proteins are covalently linked many times
on their surface to the small peptide ubiquitin to mark them as damaged and send them
for elimination to the proteosome. The ubiquitination of the PAs provides the means to
identify them. Figure 5 is data from previous experiment in Dr. DeGracia’s lab showing
PAs detected by Western blot. This data shows PAs smear from 100-200 kDa on SDS-
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PAGE after ubiquitin Western
blot. Samples are NIC, 24R and
48R after 10 min ischemia for
CA1 and CA3. Four dissections
were pooled for each lane. Only
one replicate is there for each
experimental group. In Figure 5B
is shown density of 100-200 kDa
smears. It is seen PAs increase Figure 5: Western blot for ubiquinated smear to
show PAs in CA1 and CA3.
at 24R and 48R in CA1, but
increase and decrease in CA3. My work will reproduce the similar method as explained
below.
For this Aim 1, PAs were measured by Western blot for ubiquitinated proteins
and carefully quantified by densitometry. This project’s goal was to obtain the most
reliable quantification of PAs as a function of time from microdissected hippocampal
CA1 and CA3 after 10 min global brain ischemia. CA1 dies and CA3 survives the
ischemia, therefore the D estimate in CA1 is expected to exceed CA3.
2.2 Overall Design of Aim 1 Experiments
Figure 7 illustrates the overall design for Aim 1. Experimental groups are
1.

nonischemic controls (NIC)

2.

10 min ischemia and 30 min reperfusion (30mR)

3.

10 min ischemia and 8 hr reperfusion (8R)

4.

10 min ischemia and 16 hr reperfusion (16R)
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5.

10 min ischemia and 24 hr reperfusion (24R)

6.

10 min ischemia and 48 hr reperfusion (48R)

7.

10 min ischemia and 72 hr reperfusion (72R)

Because of the need to pool samples as shown above in Figure 5, and to give
enough material to ensure at least 3 lanes of PAs per experimental group, there will be
15 animals per each experimental group to be pooled as described below. The time
course was chosen to be 72 hr because CA1 dies in 72 hrs after 10 min global ischemia
(Figure 6). The other time points are based on the extensive knowledge of global
ischemia. It is known that CA3 has returned to normal by many measures by 24 – 36 hr
reperfusion. So three time points (30mR, 8R, and 16R) sample when both CA1 and
CA3 show evidence of damage, and after CA3 has recovered (24R, 48R and 72R).

Figure 6: 10 min global brain ischemia kills CA1 but not CA3.
The general design is shown in Figure 7 (using NIC to illustrate the work flow).
CA1 and CA3 were dissected bilaterally then homogenized, then centrifuged to give the
heavy, low speed pellet containing PAs106.

This fraction was further processed as

described below to give a fraction that was treated in a high salt and detergent solution.
Whatever was insoluble in this solution was by definition a PA.

A PA pellet was

obtained from centrifugation, run on SDS-PAGE, then Western blotted using antiubiquitin antisera. The film exposures were carefully quantified as described below to
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give PA levels at each time point in CA1 and CA3. The plots of PA levels versus time
were then taken as the estimates of D as a function of time in CA1 and CA3.

Estimate D Experimental Protocol
NIC(15)
dissect regions
CA1(15)

CA3(15)
pool samples

N1‐1(5)

N1‐2(5)

Homogenize,
centrifuge
prepare PA‐containing
fraction

high salt/detergent wash
centrifuge

N1‐3(5)

N3‐1(5)

N3‐2(5)

N3‐3(5)

Homogenize,
centrifuge
prepare PA‐containing
fraction

high salt/detergent wash
centrifuge

protein aggregate pellet

protein aggregate pellet

SDS‐PAGE,
anti‐ubiquitin Western blot,
densitometry

SDS‐PAGE,
anti‐ubiquitin Western blot,
densitometry

Figure 7: Procedure to isolate protein aggregates to estimate D, total damage
2.2 Materials and Methods
Materials: Ubiquitin Conjugating Kit was from Enzo Life Sciences (Farmingdale,
NY). Mouse anti-ubiquitinated protein antisera was from Cell Signaling Technology
(Danvers, MA). Nuclear and Cytoplasmic Extraction Reagents kit was from ThermoFisher (Waltham, MA). Amersham ECL Western Blotting Detection Reagent was from
GE Healthcare Life Sciences (Pittsburgh, PA). Secondary antisera and sheep serum
were from Sigma-Aldrich (St. Louis, MO). All other chemicals were molecular biology
grade.
Ischemia Rat Model: Long Evan male rats weighing 300-325 gram were subject
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to 10 minutes of global brain ischemia and various durations of reperfusion. A total of
123 animals in the experimental groups shown above were used. Animal experiments
were approved by the Wayne State University Animal Investigation Committee and
were performed in accordance with the Guide for the Care and Use of Laboratory
Animals (National Research Council, revised 1996). In order to induce global brain
ischemia, we performed the bilateral carotid artery (two-vessel) occlusion and
hypovolemic hypotension (2VO/HT) surgery model as previously described by Smith et
al20,69,75,114. Nonischemic controls (NIC) were given sham surgery but no ischemia. All
animals were maintained normothermic at 37oC during ischemia and for the first 1 hour
of reperfusion. Temperature control is important because even a slightly lower of body
temperature can prevent cell death. Each of experimental groups consists of at least 15
animals (n=15). Experimental groups were given above.
The rats were induced with 5% halothane anesthetic agent prior the starting of
the surgery. The dose was maintained at 2% halothane plus 100% O2 during the
surgery through a nosecone. Core body temperature was maintained at a constant level
at 37 ± 0.5° C with a homeostatic blanket system for ischemia period and then 1 hour of
reperfusion. The temperature was measured by a rectal temperature probe. A
thermistor was applied in a temporalis muscle to maintain head temperature at a
constant level approximately 37 + 1° C by using heat lamp. A catheter connected to a
blood pressure machine was inserted to the tail artery to monitor mean arterial pressure
(MAP) during the surgery. A neck incision was carefully made to access both of the
common carotid arteries and the vagus nerve was avoided to disturb. Another incision
was made in the inguinal are to access and insert a catheter to the femoral artery. This
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femoral artery was used to withdrawal blood in order to cause hypovolemia.

After

succeeding the insertion process of the catheter to the vessel, ischemia was induced by
the withdrawal of ten ml of blood until the MAP is reduced to 50 mmHg. Then both of
the carotid arteries were clamped by using micro-aneurysm clips to induce global
ischemia which was applied for 10 minutes. At the end of 10 min, the blood was
reintroduced to the femoral artery at 5 ml/min. Next, all the vascular access points were
sutured. The temperature of 37 °C and full anesthesia were kept constant for 1 hour of
reperfusion. Rats were kept at a 12 hour light/dark cycle in post-operative period. Rats
were provided access to water and food freely during the reperfusion time after return to
cage. Some post-operative exclusion criteria were applied. If rats lost more than 15% of
starting body weight for one day or showed seizures, they were excluded. The survival
rate for all reperfusion groups was 75-80%.
Microdissection of brain regions: After skull opening, brains were carefully
pulled using a Rongeur rinsed in DEPC-H20. Next the brain was snap frozen for ten
seconds in the ethanol bath containing dry-ice to prevent the softening and breakdown
of the brain tissue.

Then the brain was positioned carefully in the brain blocker (Kopf

Instruments, Tujunga, CA, USA) to expose the hippocampal region. Coronal slices were
taken at posterior to Bregma in the coordinates from -2.44 mm to -4.78 mm115 , then
immediately snap frozen in dry ice-ethanol bath, to maintain a semi-frozen brain slices.
The brain was placed under dissecting microscope which pre- zapped with RNase
wipes and cooled by a small piece of dry ice to obtain a hippocampal CA1 and CA3
dissection.
To obtain CA3, a vertical cut was made bilaterally, medial to the curve of CA3
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border. Then, the CA3 region was cleaned by peeling the surrounding cortex. Next, to
obtain a CA1, a cut was made horizontally above the dentate gyrus, marked by a line
configuration of a continuous, cross-sectional blood vessels. Hippocampal CA1 brain
region is located superior from this blood vessels. Next, cerebral cortex was removed
from the piece at corpus callosum to give a final CA1 section. These procedures were
applied to both hippocampal region bilaterally. CA1 and CA3 pieces of tissue were
placed individually in a pre-weighed RNase-free Eppendorf tubes and weighted
immediately. After weighing procedure, all samples in Eppendorf tubes were frozen in
dry-ice ethanol bath and then kept at -80o C freezer until the next experiments. An
average of 15-20 mg wet weight tissue was collected for each individual CA1 and CA3
in one rat. Cerebral cortex was also dissected by slicing forebrain from -2.44 mm
posterior to Bregma to the front of brain using the brain blocker as a marker. The tissue
is also frozen in RNase free Eppendorf using ethanol dry-ice bath and kept at -80 °C for
further usage.
HSP70 validation of ischemia surgery: For each experimental group, a control
was performed to determine the quality of the ischemia surgery. The forebrain was
thawed, 100 mg cerebral cortical gray matter was shaved from the frontoparietal lobes,
immediately homogenized at 1:10 (w/v) in ice-cold buffer of 50 mM HEPES, pH 7.4, 150
mM NaCl, 1 mM EDTA, 25 mM DTT, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 5.2 μl/ml
protease inhibitor cocktail (Sigma). This unfractionated homogenates was centrifuged to
give the post-mitochondrial supernatant (PMS). After Lowry assay to determine protein
concentrations, each experimental rat was run at 125 micrograms protein in a lane on
SDS-PAGE gels and then Western blotted for HSP70 protein57. After boiling for 90 sec
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in 2x Laemmli buffer, 125 μg of each rat cerebral cortex PMS was run on 10% SDSPAGE gels at 25 mA/gel at constant current. The gel was transferred to nitrocellulose
using constant current at 100 Ma, overnight. The primary anti-HSP70 was incubated 1
hour at 1:1000 dilution at room temperature and the secondary antibody at 1:15000 was
at room temperature for 45 min. The main buffer was Tris buffered saline with 2%
Tween-20 (TTBS), and 7-4-4 min washes between all steps using TTBS. Membrane
was blocked with 5 % low-fat milk in TTBS prior to the primary antibody. Any samples
that did not contain HSP70 in cerebral cortex were excluded.
HSP70 is a stress response protein not present in control rats, but is produced in
high quantities after brain ischemia. HSP70 indicates successful ischemia in a rat.
Those rats displaying HSP70 signal were kept and those not displaying it were
eliminated from the study. On average, 85% of the rats in the reperfusion groups
showed HSP70 signal (Table 1). HSP70 was detected in cerebral cortex to prove
ischemia occurred during surgery. Figure 8 shows representatives cortical HSP70 of
samples for 8R group. Every sample was tested for HSP70 in cerebral cortex before
further processing. All of HSP70 data for both D and S estimation are shown in
Appendix B.

Figure 8: HSP 70 in 8R samples chose for further processing.
The HSP70 was only used to validate the surgeries. We could not use it to satisfy
the Aims of this Dissertation because: (1) HSP70 is a single pathway and the nature of
D requires a marker that derives from multiple upstream pathways, such as PAs, (2)
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cerebral cortex is heterogeneous in cell types, containing dozens of types of pyramidal
neurons and interneurons, as well as glia and blood vessels whereas CA1 and CA3 in
contrast are ~90% the same cell type, the respective pyramidal neurons, and (3) the
cerebral cortical cells producing HSP70 change over time, being neurons early on, then
blood vessels and glia also produce HSP70 at later reperfusion121. Hippocampus was
more suitable to test the Aims than cerebral cortex. However, there was not enough
material to directly test HSP70 in the hippocampal dissections and cortex was used
fortuitously to serve this purpose. Given this purpose, we did not quantify the HSP70 but
instead treated it as a binary outcome: it was either present or absent, and if absent
from a reperfused animal, that animal was excluded from the study.
An average of 85% of reperfused rats produced cortical HSP70. From all
experimental samples prepared for PA isolation, the break down by group of HSP70
antibody detection is shown in Table 1.
Table 1: Percent samples showing HSP70 per group
NIC
30mR
8R
16R
24R
n HSP70
na
15
16
12
15
n total
na
15
18
19
18
percent
na
100.0% 88.9% 63.2% 83.3%

48R
16
18
88.9%

72R
16
19
84.2%

Treatment of Pooled CA1 and CA3 for Protein Aggregates: Below is the
general protocol for isolating PA to estimate D as depicted above in Figure 7. Of the
rats with HSP70, the corresponding CA1 and CA3 microdissections were randomly
pooled within each experimental group to give a total of 50 mg wet weight which is
required to extract enough PAs to be able to detect by Western blot (as was determined
by prior pilot experiments).
The pooled CA1 and CA3 tissues were homogenized in Cytoplasmic Extraction
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Reagent I (CER I). Samples were then centrifuged for 10 minutes at 16,000 rpm and
4oC. The pellet fraction was taken for further processing because the PAs run in the
dense fractions of the cell108. The pellet fraction p1 was subject to the nuclear isolation
and lysis kit using the Nuclear and Cytoplasmic Extraction Reagents following the
manufacturer’s instructions. Pellet p1 was vortexed for 15 seconds, and incubated on
ice for 10 minutes. Cytoplasmic Extraction Reagent II (CER II) was added, then sample
was vortexed for 5 seconds, incubated on ice for 1 minute, and vortexed again for 5
seconds. Sample was then centrifuged for 5 minutes at 16,000 rpm and stored at -80oC
overnight. Then, p1 pellets were thawed, suspended in Nuclear Extraction Reagent
(NER), vortexed for 15 seconds, and then incubated on ice for four periods of 10
minutes, vortexed for 15 seconds after each period. Pellet samples were then
centrifuged at 16,000 rpm for 10 min at 4oC. The resulting pellet, p2, was used as input
for the PA isolation procedure.
PAs were isolated by the method of Liu et al (2005)108. Pellet p2 was dissolved in
a solution containing 2% Triton X-100 and 400 mM KCl and rocked on a rotator for 30
min at 4oC. This solution dissolves all but the most insoluble substances. PAs are
defined at those substances which cannot be dissolved in this solution. After rocking,
the samples were centrifuged at 10,000 rpm for 10 min at room temperature. The
resulting pellet, p3, was the PA fraction. Pellet p3 was dissolved in 25 L of 1X
homogenization buffer. Two microliter aliquots were taken for Lowry protein
determination. The remainder was mixed with equal volume 2X SDS-PAGE loading
buffer, vortexed vigorously to facilitate dissolving, and then boiled for 2 minutes.
In Vitro Ubiquinated Protein Reaction: To provide a sample that we knew
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would be constant from gel to gel, we ran an in vitro reaction to make PAs in the test
tube using a HeLa lysate fraction enriched in the ubiquitination enzymes (“control PA”),
following the kit manufactures instructions. Enough control PAs were prepared to run at
least 20 lanes total.
SDS-PAGE and Western Blot: SDS-PAGE gels were 10% running gel and 4%
stacking gel. Fifty micrograms of each sample were loaded per lane. Each gel also
contained a lane for molecular weight markers and two lanes of control PAs, using 3
and 1.5 microliters of control PA solution. Experimental groups were partitioned among
the gels so that those with less PAs would be on the same gel and those with greater
PAs would be on the same gels, to facilitate equalizing film exposure times after
Western blotting and to avoid large differences in PA signals that would complicate film
exposures. Gels were run at a 25mA/gel constant current for 6 hr. Gels were then
equilibrated in electroblot transfer buffer for 15 minutes before electroblotting at 100 mA
constant current overnight for 16 hrs. After, nitrocellulose membranes were fixed in 25%
isopropyl alcohol and 14% glacial acetic acid for 15 min at room temperature then
rinsed 10 times in distilled H2O and stored at 4oC until used.
For Western blotting, membranes were blocked 5% low fat milk in TTBS and
rocked for 45 minutes at room temperature. Primary anti-ubiquitin antisera were applied
at 1:1000 overnight at 4oC with rocking. Secondary antisera was applied at 1:15,000 for
45 min at room temperature. Between all treatments, membranes received three quick
rinses with TTBS and seven, four, and four minutes TTBS washes. After final washes,
ECL reagent was applied to initiate light emission. Multiple exposure times were taken
to determine the optimal exposure time for each membrane. At least three exposures of
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each membrane ranged from ~ 1 to 5 minutes each.
Gels Run: There were three gel runs to ensure proper quantification of the main
dataset of CA1 and CA3 samples. (1) A pilot gel was run with 1 sample from each
experimental group to determine the relative intensities of the PAs to determine how to
set up the main gels containing all samples. (2) The main set of six gels ran the pooled
CA1 and CA3 experimental groups. (3) A final gel was run with 1 sample from each of
the six main data gels, along with the 1.5

L control PAs to determine the ratio of

sample to control PA as a check on the main gel set.
Data Analysis: All films were analyzed by scanning densitometry. 24-bit scans
of each film exposure were obtained on a flatbed scanner (Microtek, ScanMaker
9800XL) and converted to 8-bit in Photoshop (ver. 8). NIH ImageJ software (Version
1.51p, 2017) was used to study each exposure for over- and under-development.
GelAnalyzer2 (GA2) was used to determine lane densities on optimally exposed films.
GA2 was preferable to ImageJ because it allowed better background correction and
provided volumetric density analysis of the lanes. In contrast ImageJ only provided the
area under the curve of a line drawn from the top to bottom length of a lane. Final data
were expressed as averages +/- 2 sigma (2, 95% confidence intervals).
2.3 Results
The main data set of PA Westerns, including all exposures, is shown in Figures
9-14. The optimal exposure of each of the six Western blots was determined. Figure 15
(left) is example of one exposure sets for one membrane from the main data set. Figure
15 (right) shows line scan densitometry for those exposures that makes a series of
peaks and valleys. The decision to choose one exposure as optimal required maximum
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peak heights plus maximum peak-to-peak height. If under exposed, the peaks would be
less than maximum. If over exposed, the peak-to-peak height decreased. For example
of Figure 10, the orange curve, exposure B was found to be the optimum exposure.
Figure 16 shows the line densities for all six exposure sets.

Figure 9: PA Data Gel 1 exposures
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Figure 10: PA Data Gel 2 exposures
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Figure 11: PA Data Gel 3 exposures
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Figure 12: PA Data Gel 4 exposures
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Figure 13: PA Data Gel 5 exposures
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Figure 14: PA Data Gel 6 exposures
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Figure 15: Densitometry of exposure sets Left. Three exposures of same membrane
containing 8R, 16R, and 24R CA3 PA samples. Right. Line density scans performed in
ImageJ for the corresponding exposures.

Figure 16: Image J analysis of the exposure sets of each of the six main data gels.
After determining the optimal exposure, we needed to quantify the densities so
we could compare densities from blot to blot since there were too many samples to run
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on a single gel. The control PA lanes was intended for this use. The PA control lanes
was to provide a normalizer, a denominator, for each of the sample lanes, allowing us to
compare lanes from gel to gel.
To check if this was correct, we added two lanes of PA control to each gel, one
with twice the amount than the other. There should have been a 2-fold difference
between the PA control lanes.

However, the optimal exposures as determined by

ImageJ analysis showed that in some cases, there was not a 2-fold difference between
the control PA lanes (Table 2).

Therefore, we could not simply divide the sample

densities by the control PA densities to compare across all six data gels.
Table 2: Densitometric ratio of PA control lanes for optimal exposures.
gel1D gel2B
gel3B
gel4D
gel5D
gel6C
1.6
1.9
1.6
2.4
1.8
3.1
Should be 2.

We therefore did a second strategy to normalize the main data gels. We ran a gel
that contained one sample from each of the six main data gels as well as the PA control
lane (Figure 17). As above, multiple exposures were taken and the optimal exposure
determined. From this exposure the ratio of 1.5 L control PA to the sample was taken
and then compared to the same ratio on the corresponding gel from the main data set. If
the densities were the same, the ratio of the ratios should be equal to 1. As seen in
Table 3 “main/test” column, most of the samples were close to 1, but ranged from 0.62
to 1.14. Therefore, to normalize the density of the six main data Westerns, the density
from each optimal exposure was multiplied by the value in the main/text column. This
then normalized all six blots of the main data set to the same basis.
Together, the steps above constituted our best efforts to ensure adequate
quantification of the PA density of the main data gels. To summarize: (1) the optimal
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exposure of each blot was determined, and (2) the ratio of PA control to sample was
corrected based on the test gel (Figure 17) that independently measured the ratio of a
specific sample on one of the test gels to the PA control.

Figure 17: Ratio of control PA (cPA) to sample. One or more samples from each
main data gel was run on this test gel along with the control PA to check the ratio of that
sample to the PA control. The variance between the control PA/sample ratio was
corrected as per Table 3, main/test column.
Rescaling of Data: At this stage, the data, although normalized and comparable
across all 6 blots, was still in arbitrary volumetric density units. Therefore, to finalize the
data analysis the following steps were performed: (1) each sample density (corrected as
described above) was divided by the 1.5 microliter control PA density, (2) the groups
were averaged and standard deviation calculated, (3) the NIC average was taken as
baseline zero and subtracted from the average of each reperfused group, (4) Finally,
the data was rescaled to 1.0 by taking the largest average density in either CA1 or CA3
as the denominator for all samples. The largest average value that divided all the other
CA1 and CA3 values was from CA1 at 48R.
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Table 3: Ratio of control PA (cPA) to sample.

(Test column) for gel in Figure 11,
compared to the same ratio from main
data set (main). Main/test is ratio of the
ratios and was used to correct the main
data set densities to ensure the densities
across all six gels were on the same
basis.

Calculation of variances: Standard deviations were expressed as 95%
confidence interval using the formula:

√

(11)

X is the mean, Z is the Z-value from standard z tables, s is the standard
deviation, n is the number of samples.
The final data is shown plotted as rescaled averages + 95% CI in Figure 18,
where this is to be taken as the estimate of D in the nonlinear dynamical theory of cell
injury. As seen here and in Figure 11, the PA density, which is our D estimate, is
significantly greater in CA1 than in CA3 at the 95% confidence level.
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Figure 18: Final plot of PA data to estimate D with respect to time.
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CHAPTER 3 - POLYSOME MRNA CHANGES AS ESTIMATORS OF S
3.1 Introduction
As previously described in Chapter 1, many new mRNAs made during brain I/R
come from stress responses like heat shock, UPR, anti-oxidant response, NFkB, DNA
repair genes and others. These genes make proteins to protect the cell. For example,
HSP70 protein helps refold denatured proteins by binding to exposed interior sites and
allowing the target protein to achieve its native conformation. But, also stated above, if
mRNA increases, it will not always be translated to protein. One example is an egg cell
that makes many mRNAs that are not translated until fertilization and prior to
fertilization, the mRNAs are bound to proteins that inhibit their translation122. However, it
is not mRNAs, but functional proteins that remove and repair cell damage. But we
cannot measure every protein for every new mRNA. As a surrogate of mRNAs that are
likely in the process of being translated, we can measure mRNA on polyribosomes.
Estimating the total stress responses in the cell is also problematic. There are
two categories of stress response: (1) gene independent and (2) gene dependent. Gene
independent responses are those already present in the cell and triggered by the
accumulation of damage. An example was given above of the taurine system that uses
existing anion channels to normalize intracellular tonicity. Gene dependent stress
response are those in which cell damage triggers changes in gene expression, the new
mRNA is made (transcribed) and then translated to protein, where the new protein
serves a role in stopping or cleaning up the damage. We assume that both gene
dependent and independent stress responses will vary in a qualitatively similar fashion.
That is, both will increase with injury magnitude to a point, and then decline with injury
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magnitude (as shown in Figure 2). With this assumption, we can measure one as an
estimate of both. There are many gene independent responses, and it is not technically
feasible to measure all of them. However, the total gene dependent responses can be
measured using microarray technology. Therefore, we used microarrays to measure
gene expression changes to estimate S, knowing this will provide a lower limit of the
real value.
3.2 Overview of Experimental Designs
The design of Aim 2 was similar to Aim 1.

The same experimental groups

described in Aim 1were repeated. The number of animals per group was determined by
how much total and polysome RNA was isolated from a single bilateral dissection of
CA1 or CA3. It required pooling 5 rats to provide 80 mg wet wt. of tissue to produce 1
g of polysome RNA to run on a microarray, as well as 1 g of total RNA. Total and
polysome RNA was isolated

NIC(15)

from CA1 and CA3 of the

dissect regions
CA1(15)

same experimental groups in

CA3(15)
pool samples

Aim 1. The overall workflow is
N1‐1(5)

N1‐2(5)

N1‐3(5)

N3‐1(5)

N3‐2(5)

N3‐3(5)

illustrated in Figure 19.
Homogenize,
centrifuge
PMS
extract

Figure 19: Estimate S
experimental
protocol.
Procedure to isolate total and
polysome mRNA for estimating
S, total stress response. NIC is
used to illustrate workflow.

polysome pellet

Homogenize,
centrifuge

total RNA

microarray

PMS
extract

polysome pellet

extract

extract

polysome RNA

polysome RNA

microarray

microarray

total RNA

microarray
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CA1 and CA3 were microdissected and pooled as described above, then
homogenized, centrifuged, and post-mitochondrial supernatant obtained. Twenty
percent of PMS was suitable to obtain total RNA by TRIzol extraction. The remaining
PMS was used to concentrate polysomes using the sucrose pad centrifugation method.
RNA was extracted by TRIzol from the polysome pellet. Both total and polysome RNA
were shipped to the company, Genome Explorations (Memphis, TN), who performed
the microarrays. Genome Explorations returned to us the files containing the raw
microarray data. In addition, Genome Explorations performed digital PCR of known
transcripts used to spike our samples. This allowed conversion of the microarray raw
data to copy number (CN) which is the number of mRNA transcripts per ng of RNA.
We then performed analysis of the microarray data to determine how to use it to
obtain a numerical estimate of S, the total stress response. The analyses performed are
listed here and detailed descriptions given ahead:
1.

Determining the correct method of pre-processing which includes: (1)
background subtraction, (2) probe summation, and (3) chip normalization
to compare results across microarray chips.

2.

Three ways to calculate the multi-dimensional distance (MDD) were
tested. MDD was the method we used to express microarray results as
numerical estimates of S.

3.

MDDs calculated from total and polysome RNA were compared. MDDs
from polysome RNA, but not total RNA, were consistent with the
theoretical expectations.

4.

We performed convention bioinformatics, varying the statistical stringency,
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on the polysome RNA microarrays to compare to MDD calculations.
The final result, analogous to that of Aim 2, was a quantitative expression of how
polysome mRNAs changed with time after ischemic injury, which served as the
numerical estimate of the S time courses in CA1 and CA3.
3.2 Materials and Methods
Materials: TRIzol was from Thermo Fisher Scientific Inc. RNase Zap was
purchased

from

Invitrogen

(Carlsbad,

CA).

Diethylpyrocarbonate

(DEPC),

cycloheximide (CHX), donkey anti-rabbit (NA934) and all other reagent grade chemicals
are from Sigma-Aldrich (Saint Louis, MO). HSP70 antiserum (SPA-820) was from Enzo
Life Science (Farmingdale, NY).
Animal surgery, microdissections, and sample pooling: Surgery were
performed with the same method as previously described in Chapter 2, using 2VO/HT
surgery model which induced 10 min of global brain ischemia in rats. Experimental
groups were identical to those in Chapter 2. A total of 105 rats (15 animals x 7 groups)
including NIC were used for Aim 2. After brain I/R surgery, hippocampal CA1 and CA3
were dissected as previously described in Chapter 2, except all procedures were
maintained in RNase free working condition, in order to minimize RNase contamination
(described in more detail ahead). After microdissection, tissue was kept frozen in -80oC
until use. Also, for each experimental group, the cerebral cortex was used to test for the
presence of HSP70 protein as described in Chapter 2. The RNA abbreviations used
were: CA1 polysome mRNA (CA1p), CA1 total RNA (CA1T), CA3 polysome mRNA
(CA3p), and CA3 total RNA (CA3T).
RNase free working conditions: The following precautions were made to
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minimize RNase contamination114. First, all consumables and containers were
purchased specifically as RNase-free. Second, RNase Zap (Invitrogen, Carlsbad, CA)
was used to wipe all work bench surfaces. Then, DEPC-H2O was applied five times for
washing the pre-RNase Zap surfaces. All solutions were made using ddH20 with
diethylpyrocarbonate (DEPC) dilution with the ratio 1:20 and autoclaved for 20 minutes
to inhibits RNase activity. All glassware, including the dounce homogenizers, pestles,
and Pasteur pipettes were baked at 220 °C for at least 3 hours in a pre-heated oven,
then cooled to room temperature before using in any procedures. Finally, gloves and
the face mask were necessary to wear during all procedures. All room temperature
procedures were conducted in the laminar flow hood.
Polysome pellets: All procedures were performed on ice and maintained
RNase-free conditions. Polysome pellets were isolated by the method of Khandijan et
al116. As outlined above, one replicate for polysome pellet sample was derived from
pooling five microdissections of CA1 and CA3 brain regions, to give 80 mg wet wt.
tissue. It was previously tested that 80 mg gives one microgram of polysome RNA input
for microarrays. The pooled brain regions were dounce homogenized by pestle A to
prevent rupture of the nucleus and any contamination from RNA inside the nucleus57.
Homogenization procedure was using the ratio 1:8.5 (w/v) to 1 g tissue in ice-cold
homogenization buffer consisting of 340 mM sucrose, 50 mM Tris, 1mM DTT, 5mM
MgCl2, 25mM NaCl, 300mM cycloheximide (CHX), 80U/ml RNase inhibitor (Invitrogen),
5.2 μl/ml protease inhibitor cocktail (PIC) (Sigma), pH 7.4. CHX was added to keep
polysomes intact. The homogenates were centrifugation at 9000 x g, 15 min, 4 °C to
provide post mitochondrial supernatant (PMS). Next, PMS was separated into two
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tubes. For total RNA isolation, 1/5 of PMS in RNase-free Eppendorf was vortexed with
the TRIzol addition with the ratio 1:1 and then kept at -20 °C. The other 4/5 of PMS was
taken to 1% final concentration of NP-40 for polysome pellet isolation procedure. An
800 μl miniultracentrifuge tube was used to load 350 μL of PMS above the sucrose pad.
A volume of 350 μL sucrose pad of 20% w/v sucrose, 50 mM Tris, pH 7.4, 25 mM NaCl,
5 mM MgCl2, 300 mM CHX, 1 mM DTT, 5.2 μL/ml protease inhibitor cocktail (Sigma, St.
Louis, MO, USA), and 80 U/ml RNase inhibitor (Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA) was loaded before the PMS. Samples were centrifuged at 29,400
rpm for 1.5 hr, 4 °C using the SW55 rotor. Supernatant was aspirated carefully by using
glass Pasteur pipets and discarded. The remaining pellet was the polysome pellet. The
pellet was resuspended with homogenization buffer by gentle aspiration mixing
procedure. The volume of homogenization buffer added was 500 μL for polysome pellet
and 350 ul for total RNA pellet. The polysome pellets resuspension was moved to the
RNAse free Eppendorf tubes. Finally, TRIzol reagent at 1:1 ratio of volumes to
homogenization buffer was added, and then the samples was stored at -20 °C until RNA
extracted.
RNA extraction: From the mixture of pellet resuspension with homogenization
buffer and TRIzol that has been stored in -20oC, RNA extraction procedure was
performed as instructed by vendor. The RNA pellet was resuspended in sterile ddH20,
and then flowed through the RNAeasy column (Quiagen, Valencia, CA, USA) as per
vendor instructions. After column elution process, 1

L was taken to determine the

A260:A280 ratio which was at least 1.7. The RNA concentration was given from UV
absorbance. In pilot studies, the CA1 and CA3 RNA were run into denaturing agarose
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gel electrophoresis to confirm its quality. Finally, the RNA prep was shipped overnight
to Genome Explorations (Memphis, Tennessee) on dry ice. The microarray procedures
next will be given.
Microarray procedures: All microarray procedures were done by Genome
Explorations who provided us the written methods in this and the next section. Capillary
electrophoresis procedure with RNA 6000 Nano Lab-on-a-Chip kit and the Bioanalyzer
2100 technology (Agilent Technologies, Santa Clara, CA) were performed as per the
manufacturer’s instruction to determine RNA integrity. Next, 5-25 ng per RNA sample
were transformed to cDNA. This cDNA went through an amplification and fragmentation
process, and biotin-labeled based on the manufacturer’s instructions by using the
Ovation Pico WTA, Ovation Exon Module, and Encore Biotin Module kits (NuGEN, San
Carlos, CA). The fragmented and biotin-labeled cDNA was hybridized for 17 hr at 45oC
to GeneChip Rat Gene 2.0 ST Arrays (Affymetrix, Santa Clara CA). The Rat Gene 2.0
ST array consisted of 722,254 unique 25-mer oligonucleotide features as the
representatives of all 26,309 genes in the rats. Specifically, each rat gene is
represented on the chip by the average of 27 probes along the full transcript length. In
addition, there are probe sets for several species of non-coding RNAs. In total, each
chip gave 29,489 probe sets (which we hence for refer to as ~29k). Phycoerythrinconjugated streptavidin (Life Technologies, Carlsbad, CA) was used to rinse and stain
the arrays. The wash and stain procedure were conducted in a Fluidics Station 450
(Affymetrix)

based

on

the

manufacturer’s

instructions.

The

determination

of

fluorescence intensities was performed by a GCS 3000 7G high-resolution confocal
laser scanner. Data was processed in Affymetrix GeneChip Operating Software suite,
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v.3.2. (GCOS; Affymetrix). Quality controls used GCOS quality control metrics which
consisted in mean expression of all arrays box plots and also box plots relative level of
expression.
Digital PCR: qPCR assays were conducted with molecular probes for
sequences in dap, lysA, and thr transcripts in the PolyA Control RNA (Affymetrix). The
probes were 5' 6-FAM labeled fluorescent probes with internal ZEN and 3' Iowa Black®
FQ quenchers modification (Integrated DNA Technologies, Coralville IA). The
sequences

of

the

primers

was:

dap

primer

(forward/reverse):

CTGAAGCAGCCCGCATATTA: GACCGAATTGCCTGATCACT; dap probe sequence:
ATTCAGCTAACGCTTCCAGACCGC;

lysA

primer

(forward/reverse):

CTGAAAGCACAGGTGGCATA:CTCCTCCGGATACGACATCTAA;
sequence:

TCAGTCGCAATGATTCAGCTCGCT;

thr

primer

lysA

probe

(forward/reverse):

TCACATTGCCGACTGATGAA: GGGAACAGTGACAGAGAACAG; thr probe sequence:
CCCGTGTATGAACGAAGCCGACAT; A TaqMan® Gene Expression Assay containing
a 5' 6-FAM/3" MGB quencher modified probe (Rn_99999916) was used to detect
Gapdh transcripts (Life Technologies, Carlsbad CA). Digital PCR was generated by
using the Biomark HD system, which used qdPCR 37K IFC arrays (Fluidigm, South San
Francisco,

CA).

This

allowed

standard

PCR

conditions,

as

per

vendor

recommendations. The efficiency of qPCR assay and reverse transcription reaction
were based from standard curves calculation to give digital PCR copy numbers. This is
achieved by a dilution series of pooled cRNA/cDNA and PolyA Control RNA with tenfold dilutions. The estimated target copy numbers were plotted against the reported
relative amounts for all three PolyA Control RNA assays which produced a slope with R2
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= 0.974. Furthermore, to obtain a detection of digital PCR, cDNA samples were diluted
at: 0.1X; lys, 1X; thr, 1X; Gapdh, 0.005X. The estimation for target copy numbers were
calculated by Fluidigm Digital PCR Analysis Software and changed to copy number
(CN) per ng RNA by the formula: [No. of Estimated Targets per panel]/[dPCR dilution
factor x 1.95ng cRNA/panel x RT efficiency (transcript-specific) x dPCR assay efficiency
(assay-specific)]. PLIER/Quantile-sketch generated microarray signal values (log2
transformed) for each array were converted to copy number/ng RNA values (log2
transformed) by linear regression. F-test probability values and r2 values were used to
choose the model with the best fitness which was a linear fit that did not fix the yintercept.
The final number of microarrays obtained for each group are shown in Table 4.
As seen, at least 3 replicates of microarrays was achieved for the experimental groups.
The numbers in parentheses are the number of successful digital PCR samples if
different from the total number of chips. As seen, 2 of 3 CA1p and only 1 of 3 CA3p
samples gave successful digital PCR results. For all other samples, the digital PCR was
successful for each sample.
Table 4: Number of microarrays for each experimental group.
CA1p
CA1T
CA3p
CA3T
NIC
4
4
4
4
30m
3(2)
3(1)
3
3
8R
3
4
4
4
16R
3
3
3
3
24R
3
3
3
3
48R
3
3
3
3
72R
3
3
3
3
sum total
total
22
23
23
23
91
Digital PCR (dPCR) numbers are the same except for two samples
where dPCR did not work, and the number of successful dPCR
samples are in parentheses.
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Microarray data analysis: In the following, it is to be understood that each
analysis method was performed on both the total and polysome mRNA chips as well as
on the CA1 and CA3 chips. For the sake of simplicity, these distinctions are omitted
from the following and the emphasis is placed on relative vs. copy number datasets,
which required in some instances, different ways to handle the data.
A. Chip Preprocessing: After Genome Explorations provided the microarray
data, testing of preprocessing methods was performed by us using the software
Affymetrix Expression Console (build 1.3.1.187). The software allowed six combinations
of preprocessing steps, listed in Table 5. The preprocessing methods were:
1.

Probe summation: (a) root mean average (RMA) or (b) probe logarithmic
intensity error estimation (PLEIR).

2.

Background correction: (a) perfect match (PM), (b) PM/RMA, or (c) PMCGBK (CG background correction)

3.

Normalization: (a) Square Quantile (SQ) or (b) general median (GM)

Table 5: Combinations of microarray preprocessing tested.
combination
Probe summation
BKGRND
1
RMA (median polish)
PM/RMA BC
2
RMA
PM/RMA BC
3
PLIER
PM
4
PLIER
PM
5
PLIER
PM-CGBK
6
PLIER
PM-CGBK

NORM
SQ
GM
SQ
GM
SQ
GM

Two criteria determined if a preprocessing method was acceptable: (1) how well the
chips normalized, and (2) detection of hsp70 mRNA since it is well-known that hsp70
mRNA increases > 100-fold after brain I/R in hippocampus.
B. Digital PCR: As detailed below in Results section, combination 6 was used to
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preprocess data. This transformed dataset served as input for the digital PCR (dPCR)
regression which converted all values from relative light intensity (REL) to copy number
(CN), as described above in the Digital PCR section.

The REL and CN are each

standalone datasets for expressing the microarray results.
D. Differentially Expressed Gene Lists: Table 4 gives the number of chips per
experimental group.

Conventional microarray analysis was performed on the REL

dataset using BRB Array Tools123 with no filter applied to the datasets.

Class

Comparisons Between Groups of Arrays (CCA), as implemented in BRB Array Tools,
was used to obtain differentially expressed genes (DEGs) at increasing statistical
stringency. The parameters tested (from least to most stringent) were: (1) p = 0.05/foldchange > 1.5, (2) p = 0.01/fold-change > 2, and (3) p = 0.001/fold-change > 3.
C. Probe Averaging: Using custom code written in Matlab, the REL and CN data
were averaged for each gene per experimental group. For both REL and CN, ratios of
experimental to control were calculated for each probe set for each experimental group
(REL x-fold and CN x-fold, respectively). In addition for the CN dataset, (experimental –
control) was calculated for each experimental group (CN subtract). The ratios or
differences of the ~29k probe sets amongst experimental groups relative to the NIC
group served as inputs for calculating multi-dimensional distances (MDD).
E. Multi-Dimensional Distances: MDD was calculated by the method Huang et
al111. MDD is a generalization of the 3 dimensional distance formula in x, y, z
s  (x 2  x1 ) 2  (y 2  y1 ) 2  (z 2  z1 ) 2

(12)

to any number of dimensions, n. In general, distance, s, is the square root of sum of the
squares. For n dimensions, Eq. (12) becomes:
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MDD 

n

 (x
i 1

2

 x 1 ) i2

(13)

This method treats each mRNA (probe set on the chip) as one dimension, so the
total number of mRNAs gives the total number of dimensions, n. The total number of
probe sets was n = 29,489. Eq. (13) was suitable for analyzing the CN subtraction data
where x2 is one of the reperfused groups and x1 the NIC group. When REL and CN
datasets were expressed as fold change over NICs, Eq. (13) was modified as follows:
MDD 

n

x2

(x
i 1

 1) i2

(14)

1

When a gene does not change, the fold change is 1. In Eq. (14) such a gene will
contribute zero to the distance. MDDs were calculated for each experimental group
using custom code written in Matlab. Three versions of MDD were calculated:
1.

REL MDDs using x-fold change of experimental/NIC (using Eq. 14).

2.

CN MDDs using x-fold change of experimental/NIC (using Eq. 14).

3.

CN MDDs using subtraction of controls from experimentals (using Eq. 13).

The Matlab code ran according to the following algorithm:
1.

Read in microarray data matrix that had been preprocessed as described
above (for example, for CA1p REL dataset was 22 columns, one for each
chip, by 29,489 rows of probe levels).

2.

Calculate average and standard deviation for probes of each experimental
group.

3.

Calculate MDD from averages as per Eqs. (13) or (14) as suitable.

4.

Rescale MDDs to maximum of 1.

5.

Calculate propagated error for each operation in the MDD formulas from
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standard deviations; Using Eq. (11), express final error as 95 %
confidence intervals (2 sigma, or 2).
As with the PA data, the final MDD values were scaled to the maximum value in
either CA1 or CA3, which maximum was taken to be 1. The p and T mRNA data were
scaled independent of each other. The 3 variations of MDD (REL x-fold, CN x-fold, and
CN subtract) were assessed to determine their consistency with the theoretical
expectation S.
3.3 Results
Animal Surgery and HSP70 detection: On average, 3/4 of the total rats in the
reperfusion groups showed HSP70 signal in cerebral cortex samples. Every sample
was confirmed for HSP70 in cerebral cortex to allow inclusion in the study.

All of

HSP70 data from samples used for the microarray studies are shown in Appendix B.
Polysome pellet validation:
Several methods were done to test
the quality control of the polysome
pellet procedure118. Western blot was
performed and detected ribosome
markers including ribosome protein
S6 for 40S and ribosome P antigen
(RPA) for 60S and polyA binding
protein and HuR in polysome pellet
Figure 20: Western blots and agarose gels. (A)
Western blot of ribosome markers. (B) Agarose
gel of RNA of polysome pellet. (C) Western blot of
20B shows that polysomes pellet
organelle markers.
as depicted in Figure 20A. Figure
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gave an intact ribosomal RNA from RNA extraction procedure.

There is no

contamination of mitochondria as detected in Western blot in the polysome pellets prep
by detection using cytochrome C (cyt C), pyruvate decarboxylase (PDC), or cytochrome
oxidase 4 (COX IV).

Also, the Western blot result also does not show any

contamination from endoplasmic reticulum, as there is no detection of protein disulfide
isomerase (PDI). Finally, it also does not show any nuclear contamination by NeuN
antibody detection (Figure 20C).

We previously showed approximately 1/3 of the

protein detected by liquid chromatography tandem mass spectroscopy (LC-MS/MS)
from the CA1 and CA3 polysome pellets were ribosomal protein subunits118. These
control results validated the procedure of polysome pellet isolation.
RNA quality: RNA capillary electrophoresis showed RNA was good quality for
microarray procedure with no degradation of rRNA bands. Representative samples from
the CA1p set are shown in Figure 21.

All samples were required by Genome

Explorations to pass the capillary electrophoresis test to move forward to microarray
hybridization.
Figure 21: RNA capillary
electrophoresis results
from
Genome
Explorations from CA1p
samples from (A) NIC, (B)
8hR, (C) 24R, and (D)
48R groups.
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We independently ran agarose gels in our lab and also observed no degradation
of RNA samples118.
Preprocessing Tests: A typical microarray study will report using the RMA
methods for preprocessing, which is suitable for conventional bioinformatics. Since we
needed to use the microarray data to calculate MDD, which is not a typical application,
we evaluated the various preprocessing methods (Table 5) to test how well chips
normalized and the detection of hsp70 mRNA.

As seen in Figure 22, when a

normalization method was successful, the chip histograms lay on top of each other. This
only occurred with combinations 1, 3, and 5 (green check marks in histograms). Only 2
of the combinations, numbers 5 and 6, detected hsp70 as shown by plots of hsp70
levels as a function of reperfusion time. Only combination 5, consisting of PLIER, PMCGBK, and SQ, satisfied both of our test criteria. Therefore, all chips were
preprocessed with this combination.

Figure 22: Results of chip preprocessing tests. Left plots are chip histograms, right
plots are the relative levels of hsp70 as a function of reperfusion time.
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Figure 23A shows box blots from preprocessing all microarrays simultaneously.
Only one sample visibly deviated from the normalization mean (red arrow), but was not
considered statistically different by the software and hence retained. Because the total
RNA and polysome RNA chips derived from different homogenate fractions, it is not
advised to preprocess the p and T chips together. Therefore, the CA1p and CA3p chips
(Figure 23B) were preprocessed (Figure 23C) separately from the CA1T and CA3T
chips (Figures 23D and 23E, before and after preprocessing). When this was done, no
outliers were observed.

Figure 23: Box plot of microarrays. (A) All 91 chips. CA1p and CA3p (B) before and
(C) after normalization. CA1T and CA3T chips (D) before and (E) after normalization.
The chip names are omitted because they are unreadable in these plots.
Estimating S: The final results of the three methods used to estimate S as MDD
are shown in Figure 24. The top, middle, and bottom rows are REL x-fold, CN x-fold,
and CN subtraction methods of calculating MDD, respectively. Left figures are polysome
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RNA and right are total RNA. The lines connecting the points are splines generated by
Microsoft Excel graphing software and are presented only to help visualize the data, but
the curves should not be taken as meaningful. The goal of Aim 3 will be to determine if
the points shown provide estimates of S time courses that fit curves generated by the
theory equations.
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Figure 24: MDD calculated for relative ratio microarray data. Error bars are + 2.
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In this section, we give qualitative analysis of the results by comparing the area
under the curve (AUC) of each spline, calculated using the Matlab trapz function that
performs a trapezoidal approximation of the area under the curve of a set of data points.
The magnitude of the AUC allows us to speak of one curve as “greater” or “lesser” than
another. As seen in Table 6, for all three MDD calculation methods on polysome RNA,
the AUC was greater for CA3 than for CA1 (e.g. curves in Figure 24A, C, & E). For total
RNA, the ratio MDD methods (Figure 24B & D), gave AUC for CA1 greater than CA3.
For the subtraction method on total RNA, the AUC for CA3 was greater than that of
CA1.
Table 6: Area under the curves for plots in Figure 18
CA1p
CA3p CA1T
CA3T
REL

32.1

37.8

57.0

41.2

CN

23.1

24.5

36.4

23.0

CN subtract

26.4

30.0

37.4

45.1

The initial conclusion from these results is that, as was hypothesized, the MDD
points derived from polysome RNA better fit the theory. CA1 dies but CA3 survives 10
min global ischemia. The theory indicates that the D time course for CA1 should be
greater than CA3, and that the S time course for CA3 should be greater than CA1. For
the total RNA using the x-fold methods (Figure 24B and 24D) the result opposite of what
the theory predicts is obtained. As a first pass, this data treatment is encouraging by
supporting the hypothesis and suggesting that MDD obtained from polysome RNAs may
be a reasonable estimate of S. This topic is addressed in greater detail in Chapter 4,
where the goal of Aim 3 is to fit the PA measurements and the MDDs to time course
curves calculated from the theory equations.
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MDD Compared to Differentially Expressed Genes: To determine the validity
of the MDD calculations, we wished to compare conventional microarray analysis to the
MDD values. Class Comparisons Between Groups of Arrays (CCA, implemented in
BRB Array Tools), the conventional analysis method used here, produces list of DEGs
that clear statistically at predefined p values and x-fold cut off criteria. The resulting
DEG lists give (a) gene names, (b) the x-fold difference with the control group, and (c)
the related statistics meeting the predefined criteria. CCA and other widely used
methods such as significance analysis of microarrays (SAM) use special statistical
methods, such as false discovery rates (FDRs) to account for the facts that microarrays
have a low number of replicates but a large numbers of individual observations in the
form of thousands of probe sets per microarray. Since the MDD method does not use
the more refined statistics, it was important to compare the two approaches. The way
we compared the methods was to generate DEG lists, and from the genes on the list,
calculate a list-MDD and determine how that number compared to MDD as calculated
above.
To compare the CCA results to the MDD method, CCA was run on the REL
dataset to generate DEG lists at increasingly stringent selection criteria. The three
selection criteria tested from least to most stringent were: (1) p = 0.05, x-fold > 1.5, (2)
p= 0.01, x-fold > 2, and (1) p = 0.001, x-fold > 3. A schematic illustrating the analysis
protocol is shown in Figure 25 for the comparison of the 30mR group to the NIC group
for the CA1p REL data. The comparison shown is 30mR/NIC, run three times at the
indicated stringencies, which produced three gene lists of DEGs. The image is meant to
illustrate that, as stringency weakens, the CCA method captures larger lists of genes.
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CCA was run also for 8R/NIC, 16R/NIC, 24R/NIC, 48R/NIC, and 72R/N. For each
comparison, 3 lists were produced, leading to a total of 18 DEG lists for CA1p, and 18
lists for each of CA3p, CA1T, and CA3T, for a total of 18 x 4 = 72 DEG lists generated
in this analysis.
Each of the 72 CCA DEGs lists provided a list of genes, and also the x-fold
difference of that gene with the control group. The x-fold differences on a given list
could be plugged into Eq. (14) to generate a “list-MDD” for that DEG list. Thus, 72 DEG
“list-MDDs” were calculated. In turn, the list-MDD could be compared to the MDD as
calculated by Eq. (14) that used all 29,489 probes on the microarray chips. Clearly, a
list-MDD will be smaller and be some percentage of the MDD calculated by Eq. (14).
The percentages were calculated and tabulated, along with the number of DEGs
detected at each stringency, and what percent of the 29,489 probes the DEG list
represented. Averages were taken per stringency, and the final results are tabulated in
Table 7.

CA1p: N, 30mR, 8R, 16R, 24R, 48R, 72R

p 0.001 0.01 0.05
list 1
g1
g2
…
gn

list 2
g1
g2
g3
…
gm

list 3
g1
g2
g3
g4
…
go

Figure 25: Overview of CCA tests
performed on REL dataset. Shown is
the comparison of the 30mR group to the
NIC control group for the CA1p subset of
the REL dataset. List 1 has n DEGs, list 2
has m DEGs and list 3 has o DEGs
where n < m < o.
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Table 7: Comparison of CCA and MDD.
1.5 (0.05)
% list-MDD/MDD
81% + 11%
# DEGs
2584 + 620
% of all PS
8.8% + 2.1%

2(0.01)
65% + 14%
498 + 191
1.7% + 0.8%

3(0.001)
48% + 14%
64 + 43
0.2% + 0.15%

Row 1 is the percent of list-MDD to total MDD using all genes. Row 2 is the number of genes per DEG
list. Row 3 is the percent of the # of DEGs out of all 29,289 probes on the chips. Column headings are the
stringency criteria: x-fold cutoff (p value). All values are means + standard deviations.

As seen in Table 7, at p = 0.05 with 1.5 fold cutoff, on average, CCA detected
~2500 DEGs across all experimental group comparisons with the controls. As expected,
the number of differentially expressed genes decreased with increasing stringency,
decreasing to ~500, and ~65 at p = 0.01 and 0.001, respectively. These numbers of
genes represent about 9%, 2% and 0.2% of all genes on the microarray.

The

corresponding list-MDDs account for ~80%, ~65%, and ~50% of the MDD calculated
using all 29,489 probes.
When it is considered that CCA criteria of p < 0.05 and cutoff of 1.5 most closely
approximate the parameters used in many conventional microarray studies, we can
conclude that about 80% of the MDD used in to generate the Figures 18A and 18B
would be detected by conventional microarray analysis. The remaining 20% would be
considered statistical noise and discarded by conventional methods. However, we have
posited that D and S form networks in the cell, and with our calculation of MDD using all
29,489 probes, we can alternatively interpret the 20% as low intensity network
components that are missed by convention microarray analysis. The present studies
provide no evidence to support or refute this interpretation, but our analysis here raises
this alternative possibility.
In conclusion, this section has developed some concrete evidence that using
MDDs as we have in this study give results consistent with a typical microarray analysis
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by showing that a typical microarray analysis would detect ~80% of the signal we
obtained with the MDD calculation that used every gene on the microarray.

We

consider this an initial validation of the MDD values plotted in Figure 26, which justified
moving forward to fit this data to the mathematical equations of the acute injury theory.
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CHAPTER 4 - FITTING THE DATA TO THE THEORY
4.1 Introduction
Aim 1 estimated D as a function of time in CA1 and CA3 by measuring levels of
PAs following 10 min of global brain ischemia and a time course to 72 hr of reperfusion.
Aim 2 estimated S in CA1 and CA3 by quantifying changes in polysome mRNAs along
the same time course. The measurement of PAs by densitometry gave a single final
answer but there were alternate ways to process the microarray data giving three
possible estimates of S. The three methods were: (1) REL x-fold, (2) CN x-fold, and (3)
CN subtraction. Combining the PA data with each of the three MA analyses gave three
final data sets of the estimates of D and S as a function of time, which are displayed in
Figure 26. In the 1st and 2nd columns are the CA1 and CA3 D and S time course
estimates, respectively. The 3rd column plots D versus S to give the trajectories of CA1
and CA3. The curves depicted in Figure 26 are spline fits automatically generated by
MS Excel but these are not theoretically-relevant curves passing through the data
points. The goal of Aim 3 is to determine if the theoretical equations can provide curves
that pass through the data points, within the specified 2 error.
4.2 Overview of Aim 3
To achieve the goal of Aim 3 requires expanding the theory to better account for
cell injury. Chapter 1 described the single injury autonomous model, where
“autonomous” is a technical mathematical term meaning that time, t, is absent from the
right hand side of an ordinary differential equation. The autonomous model has
limitations that make it a poor candidate for fitting experimental data. Therefore,
described ahead is the nonautonomous single injury model (SIM), which is a more
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realistic model of cell injury. The SIM allows construction of multi-injury models (MIM).
We will then compare the trajectories from the SIM to the data trajectories (third column,
Figure 26) as a decision criteria for which dataset to fit. We show below that our present
best fit of the experimental data points used a MIM construction. We close this chapter
with an analysis of the microarray data using an independent method called MaSigPro
that detects time course trends in microarray data and provides some justification for
the use of the MIM to fit the data.
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Figure 26: Final D and S estimate data sets. (A) REL x-fold; (B) CN x-fold; (C) CN
subtraction. Columns 1 and 2 are CA1and CA3 D and S time course estimates,
respectively. Column 3 are D/S trajectories. All error bars are +2.
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4.3 Critique of the Autonomous Model
In Chapter 1 it was discussed how the autonomous model requires
concatenation (“gluing”) of two separate systems of ODEs to generate a theory that
accounts for how injured cells recover or die. The figure is repeated as Figure 27. The
main theory equations (Eq. (1), Chapter 1) generate time courses that end in attractor
states. The attractor states represent the maximum deviation from the control state.
However, the system stays at the attractor for all time after achieving this state, which is
unrealistic for cell injury. Instead, we would expect, at a given magnitude of injury, I,
that the system would deviate to a maximal state away from control, where there is
maximum buildup

Figure 27: Illustrating the need to concatenate two ODE systems to generate
“uphill” and “downhill” components of an injury time course.
of damage or stress responses at some time t after then injury. But after this point, we
expect the system to either recover or die. That means the system must return to (D, S)
= (0, 0) where there is no damage or stress responses in the cell. This would happen if
the cell recovered (S* > D*) or if the cell died (D* > S*). In the autonomous model, this
problem is dealt with by making an artificial assumption that when the injured system
hits the attractor state (D*, S*) that immediately Eq. (1) no longer applies and a second
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ODE system, the “downhill” ODE (Figure 27) takes over. The second ODE system
describes the exponential decay from (D*, S*) to (0, 0), where the rate of decay is given
by |D* -S* |, as illustrated in Figure 21. It is preferred to have a system of differential
equations where all of this happens in one system and does not require artificially
“gluing’ two ODE systems together, and this was the motivation for developing the
nonautonomous SIM version of the theory.
4.4 The Nonautonomous Single Injury Model
The nonautonomous single injury model (SIM) comes from modifying postulates
5 and 6 of the autonomous model. For the autonomous model, those postulates were:
Postulate 5: The velocity parameter v is constant equal to 1.
Postulate 6: The decay parameter k is constant equal to 1.
Postulate 5 is unrealistic because it says the rate constant governing the
formation of D and S is a constant which does not change with time. This implies that
the formation of D and S would be constant with time, which means they would continue
to build up without limit, after injury of magnitude I occurred. In reality, both D and S
build up for some amount of time, each reaching some maximum, and decay thereafter,
whether the cell lives or dies. Therefore, we modify postulate 5 to be more realistic by
saying that the rate of buildup of D and S decays as a function of time. The simplest
mathematical form is exponential decay. Therefore the new postulate 5 for the SIM is:

vD  vS  v0ec1t

(15)

Eq. (15) says that the rate of formation of D and S is not constant, but decreases
exponentially with time.
Postulate 6 of the autonomous model said the decay parameter k = 1. Like the v
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parameter, this is unrealistic because it says that decay is a simple exponential function
of D for the D ODE, and of S for the S ODE in the autonomous version. Although
concatenating two equations, shown in Figure 27, was artificial, it was an important step
to understand how k behaves. Instead of taking an exponential decay at (D*, S*) where
the decay rate equals |D - S|, this result suggested that k should be a function of the
instantaneous value of |D-S | as follows:

(16)

kD  kS  c2 | D S |
We can then substitute these into the autonomous model to give the SIM version
of the theory:
dD
(cD Ie I D ) n
 v0 e  c1t
 c2 | D  S | D
dt
(cD Ie I D ) n  S n

(17)

(cS Ie  I S ) n
dS
 v0 e  c1t
 c2 | D  S | S
dt
(cS Ie  I S ) n  D n
To summarize, this non-autonomous version of the theory allows for a full
progression of the injury trajectory in the phase plane, starting at (0, 0) and naturally
ending at (0, 0) and overcomes the problem of the artificial concatenation of two ODE
systems as illustrated in Figure 27. Comparison of the SIM to the autonomous model is
shown in Figure 28, where the SIM generates true closed loop trajectories that begin
and end at (D, S) = (0, 0).
4.5 Multi-injury Models
The SIM, Eq. (17), possess an additional advantage. It allows construction of
multiple injury models (MIM) where the first injury occurs at time t = 0 and another injury
can occur any time after. This is important because it allows the theory to model such
phenomena as preconditioning and post-conditioning, both of which are forms of
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sequential injuries in time. For preconditioning, a sublethal injury Isublethal, is applied at
time zero, t0, and the lethal injury Ilethal, is applied at some later time. It is well-known that
preconditioning prevents the 2nd, lethal injury from being lethal.

Figure 28: Comparing SIM output to the autonomous model. (A) Autonomous
model: green trajectory is “uphill” output of Eq. (1). The blue line is what the trajectory
from the “downhill” ODE system would look like overlaid on the uphill phase plane to
make a closed loop trajectory. (B) A true closed loop trajectory from the SIM of Eq. (17),
where I < IX, thus the system survives. Arrows depict the forward time evolution of the
trajectory. (C) The D (red) and S (green) time courses corresponding to the trajectory in
B.
A MIM also allows modeling of post-injury therapeutics, where the therapy is
treated as a sublethal injury. This is seen, for example, in hypothermia, which is a very
effective form of therapy for many forms of ischemia, including brain ischemia.
Hypothermia is indeed an injury as described by Eq. (17), where the temperature
decrement represents the intensity of injury, I. If hypothermia is too intense (high I =
large temperature decrease), it is lethal. If the temperature decrement is below IX, the
system will recover from the insult. A MIM can, in principle, model the 1st injury, say
brain ischemia, at time zero, t0, and then model the application of hypothermia at a later
time, t1.
There are many possible ways to use Eq. (17) to construct a MIM. Here we
construct one based on minimal assumptions that the D and S generated in the 2nd
injury add to the D and S generated in the 1st injury. Since there are two sequential
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injuries, we call this a 2-MIM. It consists of 2 instances of the SIM added in the following
fashion:

dD1
 nD
v n
 kD1
dt
 D  S1n  S 2 n
 nS
dS1
v n
 kS1
dt
 S  D1n  D2 n
dD2
 nD
v n
 kD2
dt
 D  S1n  S 2 n

(18)

 nS
dS 2
v n
 kS 2
dt
 S  D1n  D2 n

Where

k  c2 |(D1  D2) (S1  S2)|

(19)

As seen in Eq. (18), the D and S values from injury 1 and injury 2 add in both the
formation and decay terms. Figure 29 shows the circuit diagram corresponding to Eqs.
(18) and (19). Figure 30 shows a computation of the 2-MIM that mimics a
preconditioning response.
Figure 29: Circuit diagram of the 2-MIM given by Eqs. (18)
and (19). I1 is applied at t0 and I2 is applied at t1.
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Figure 30: Solutions of a 2-MIM that model preconditioning. D and S time courses
are red and green, respectively. A sublethal injury is given at t0 and a lethal injury
applied at (A) t = 250, (B) t = 72, and (C) t = 48. When the time between I1 and I2 is
small enough, I1 and I2 interact and the first injury causes the second injury to no longer
be lethal.
4.6 Materials and Methods
Custom code was written in Matlab (ver. R2017a) to fit the rescaled experimental
data to the SIM and MIM versions of the theory. MaSigPro analysis of microarray data
was conducted using custom scripts written for R (ver 3.2.5). Computational details are
provided below in the relevant sections.
4.7 Results
Trajectory Analysis: The first problem to consider is which of the three final
datasets (Figure 26) to fit. The approach we took to address this was to first evaluate
how the trajectories corresponded to the theory output. Figure 31 shows the CA1 (red)
and CA3 (green) trajectories along with a generic survival and death trajectory
generated by Eq. (17). Figure 31A-C are the exact same trajectories shown in Figure
26 but with the error bars removed so the trajectory paths are easier to see. Figure 31D
shows a general property of the SIM trajectories. Survival trajectories occupy the plane
to the left of the diagonal, and death trajectories occupy the plane to the right of the
diagonal. This is true for any SIM solution expressed as a trajectory.
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Figure 31: Trajectories for (A) REL x-fold microarray (MA) analysis, (B) CN x-fold MA
analysis, (C) CN subtraction MA analysis, and (D) generic survival (green) and death
(red) trajectories generate from the SIM, Eq. (17). Blue dashed line is the diagonal of
the plane.
When we evaluated the three final datasets, none of them strictly adhered to this
feature. For REL x-fold (Figure 31A) the 30 min and 72R CA1 data points (red curve)
are to the left of the diagonal. For both the CN x-fold and CN subtract (Figure 31B and
C, respectively), the 30 min CA3 data point is right of the diagonal, and the 72R CA1
point is left of the diagonal. However, for both CN datasets, the error on the 30 min data
point puts it on both sides of the diagonal (Figure 26). Thus the CN datasets most
closely adhere to the theoretical curves and we focused on them. Between the CN xfold and CN subtract curves, we find the x-fold curves had overall smaller errors (Figure
26). We therefore focused the analysis on the CN x-fold curves because the smaller
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errors created a more stringent situation for curve fitting the data to theoretical curves.
Fit Constraints: Fitting was not arbitrary. The experimental design dictated
some parameter relationships and the known outcome of CA1 and CA3 neurons
dictated others. The following list of fit constraints determined numerical choices for
equation parameters.
1.

cD and D had to be equal for CA1 and CA3 because both were subjected
to the same global ischemic insult.

2.

I had to be equal for both CA1 and CA3 because both were subjected to
the same 10 min intensity of ischemia.

3.

cS for CA3 > cS for CA1 because CA3 survives the I intensity of 10 min
ischemia and/or

4.

D for CA3 < D for CA1 because CA3 survives the I intensity of 10 min
ischemia.

5.

IX for CA1 had to be less than the I value for the fitting because CA1 dies.

6.

IX for CA3 had to be greater than the I value of the fitting because CA3
survives.

Curve Fitting: For this Dissertation analysis, the curve fitting was performed “by
eye” and using a least squares measure as an indicator of the fit quality. More
sophisticated means of data fitting were not employed for this Dissertation, and the
reasons for this are discussed in Chapter 5, Discussion.

A fit to the SIM is shown in

Figure 32, and the model parameters corresponding to the fit curves are listed in Table
8. The closer to zero are the least squares, the better the fit. The SIM did not give a
particularly good fit for either CA1 or CA3. For CA1, the least squares for the D time
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course (LSD) was 0.55, and the LSS = 0.32. For CA3, LSD = 0.38 and LSS = 0.94. In
Figure 26A, for CA1, the D time course ends in the 72R S point and the S time course
ends in the 72R D point. The fit is also poor for CA3 where the 24R and 72R S points
were not even approached by the fit curves (Figure 32C, two blue S points outside of
curves). Expectedly then, the data points did not fall on the corresponding trajectories
(Figure 32B and D).
Figure 33 shows data fits to the MIM. For these fits, CA1 was fit to a 2-MIM and
CA3 was fit to a 3-MIM. The parameters corresponding to the fitting curves are listed in
Table 9. For CA1, LSD = 0.4 and LSS = 0.3, slightly better than the SIM fits. For CA3,
LSD = 0.14 and LSS = 0.14, significantly better than the SIM fits. Fitting to the MIM
makes the unusual assumption that the additional injuries, I2 in the case of CA1, and I2
and I3 in the case of CA3, were not due to an exogenous insult, but were endogenous
to the tissue.

For both CA1 and CA3, the additional injuries had the same core

parameters (cD, D, cS, S) and varied only in the SIM parameters v0, c1, and c2,
suggesting they are due to the same mechanism, just expressed with different kinetics.
This topic will be further discussed in Chapter 5.
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C

D

Figure 32: SIM fit to CN x-fold data estimates of D (magenta points in A and C, red
points in B and D) and S (blue points in A and C, green points in B and D). (A) CA1 D
(red) and S (green) time course curves, and (B) corresponding CA1 trajectory. (C) CA3
D (red) and S (green) time course curves, and (D) corresponding CA3 trajectory. All
error bars are + 2, omitted from trajectories for clarity.
Table 8: Parameters obtained from curve fits in Figure 26.
cS
v0
c1
cD
D
S
CA1
0.04
0.02
1.5
0.25
0.175
0.05
CA3
0.04
0.02
3
0.2
0.35
0.2

c2
0.125
0.4

n
3
3
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C

D

Figure 33: MIM fits to CN x-fold data estimates of D (magenta points in A and C, red
points in B and D) and S (blue points in A and C, green points in B and D). (A) CA1 D
(red) and S (green) time course curves, and (B) corresponding CA1 trajectory. (C) CA3
D (red) and S (green) time course curves, and (D) corresponding CA3 trajectory. All
error bars are + 2. CA1 was fit with a 2-MIM, where I2 occurs at 60 hours. CA3 was fit
with a 3-MIM where I2 occurs at 14 hours and I3 at 60 hours.

Table 9: Parameters obtained from curve fits in Figure 27.
v0
cD
cS
D
S
CA1

CA3

c1

c2

n

I1

0.02

0.02

0.29

0.25

1.75

0.09

0.011

3

I2

0.001

0.015

0.5

0.1

1.5

0.1

2.5

3

I1

0.02

0.02

0.5

0.2

0.2

0.75

0.018

3

I2

0.001

0.015

0.5

0.1

1.5

0.15

1

3

I3

0.001

0.015

0.5

0.1

1.5

0.3

1.5

3
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MaSigPro Gene Expression Time Courses: We sought an unbiased approach
to complement the initial approach to fit the data points “by eye”. The microarray data
collected in this study is time dependent. Analysis methods such CCA (used in Chapter
3) are not suitable for analyzing time course microarray data. CCA and related methods
are designed to compare two conditions, for example, a drug treated and untreated
sample, and time is not a consideration in the underlying statistics. Analysis of time
courses of microarray data require some means to take into account the time aspect of
the study. Three major methods have been developed to analyze microarrays time
courses. ANOVA based methods treat time as one of the study factors. A second
method utilizes Bayesian statistics and updates expected frequencies based on
observed frequencies as time progresses. A third method seeks to cluster genes based
on how they change over time, which is the method we used here as implemented in
MaSigPro124. MaSigPro is a two-step analysis method. In step one, statistical
significance of differentially expressed genes are determined. In step two, polynomial
splines are constructed based on how a given gene changes over time. Then, genes
with statistically similar polynomial splines are clustered together. This method allows
determination of groups of genes that may increase together, decrease together, or
generally, follow the same pattern of change over time.

The clusters then can be

subject to Gene Ontology analysis to identify enriched genes, pathways, biological
processes and so on.
MaSigPro analysis was run on the REL x-fold data set because this method
requires a minimum of n = 3 observations per gene and the CN data could not meet this
criteria due to the unsuccessful dPCR of some of the 30mR samples (Table 4). The
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software was set to output 9 time course clusters for both CA1 and CA3. We next found
clusters in CA1 and CA3 that had similar temporal profiles and grouped them into 7
different groups labeled A-G (Figure 34 through Figure 38). Then, each cluster was
analyzed for gene enrichment using the Web-based Gene Set Analysis Tool-Kit
(WebGestalt:

http://www.webgestalt.org).

Finally,

the

enrichment

profiles

were

compared for each of the groups A-G between CA1 and CA3.
A total of 1711 genes were clustered in both CA1 and CA3. The number of genes
in each cluster is shown on each cluster plot in Figure 34 through Figure 38. Group A
represented genes that decreased below controls for the 72 hr duration. Group B genes
were below or at NIC levels then peaked in the 8 – 16 hr range, and persisted for the 72
hr time course. Group C genes were at or higher than control, again peaked in the 16 hr
range, then declined thereafter. Group D genes showed a continuous increase over the
72 hr reperfusion period. Group E genes peaked at 16 hrs, declined to 48 hrs, then
peaked again at 72 hrs. Group F genes started out higher than control, then
continuously declined below control levels by 72 hr. Group G genes were at or below
control, then increased rapidly at 16 hrs, persisted to 48 hrs then declined at or below
control levels by 72 hrs.
Table 10 details some of the pathways associated with each group. In general
these were different between CA1 and CA3, in spite of following similar time courses,
although there was also some overlap in pathways (highlighted terms, Table 10). It is
not our intent to focus on specific pathways per se, but to point out that this unbiased
MaSigPro analysis lends some support for the use of the MIM to model our data.
Specifically, Groups B, C, E, and G support transient activation events from ~ 8 – 16 hrs
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reperfusion. Group E (representing 117 genes in CA1 and 188 genes in CA3) also
supports a second activation event after 48 hrs. While not constituting proof for
endogenous injuries modeled by the MIM, these time course groupings support that
relatively discreet events happened in the 8-16 hr time frame, and again in the 48-72 hr
time frame, which is consistent with times chosen for additional MIM injuries used to fit
CA1 (I2 at 60 hr) and CA3 data (I2 at 14 hr and I3 at 60 hr).

Figure 34: Group A clusters detected by MaSigPro. Each Group consists of similar
time course clusters between CA1 (red) and CA3 (green). Red lines are control levels.
Green lines are composites of the time course changes of the clustered genes.
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Figure 35: Group B clusters detected by MaSigPro.
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Figure 36: Groups C & D clusters detected by MaSigPro.
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Figure 37: Group E clusters detected by MaSigPro.
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Figure 38: Groups F and G clusters detected by MaSigPro.
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Table 10: Enriched genes in the clusters in Groups A-G in CA1 and CA3.
Group
A

Temporal Behavior
Continuous decline below NIC

CA1 pathways
ion channels
ATPases
ion transporters
inflammation
cytokines
sugar & fat metabolism
histamine receptors

CA3 pathways
MAP kinase
apoptosis
IL7 - B/T cells
notch
cytokines
amino acid metabolism
CSF macrophage
heat shock
interleukin
stress responses
cytochrome p450
PLA2
prostaglandins
glutathione

B

Increase over NIC by 8hr, peak 16-24
hr, stays elevated over 72 hr.

C

Increase over NIC 16-24 hr, declines
thereafter

tRNA synthesis
heat shock
stress responses

lysosome
heat shock

D

Continuous increase over NIC

B cell
lipid PLA2
apoptosis
interferon
Platelet
cell cycle
complement

Platelet
complement
lipid PLA2
apoptosis

E

Peaks at 16 hr, declines to NIC by
48R, peaks again at 72 hr

cytokines
ion channels
amino acid metabolism

olfactory receptors
lipid metabolism
antioxidant response
terpenoids
glycans

F

Starts higher than NIC, continuous
decline to below NIC over 72 hr

FOS, IEGs
cAMP signaling
lipid enzymes

DAG/prostaglandins
PI3/glycans
carbonic anhydrase

G

Starts below NIC, peaks at 24 hr,
declines to or below NIC at 72 hrs

alpha crystallin stress
response

antioxidant response
RAS signaling

The specific gene ontology terms are not used here. Instead, pathway names are given that give an
overall functional view of the enriched genes. Pathways common to CA1 and CA3 are highlighted.
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CHAPTER 5 - DISCUSSION AND CONCLUSIONS
5.1 Overview of Discussion
To our knowledge, this is the first ever study to attempt to quantify cell injury
using theoretical equations designed to capture the dynamics of how injured cells
change as a function of time and injury intensity.

It was not the intent of this

Dissertation to test or validate the nonlinear theory of acute cell injury. Instead, the goal
of all three Aims revolved around the need to find quantitative estimates of the two
theory variables D and S. The ability to quantify D and S necessarily precedes any
attempt to test the theory itself. To this end, Aim 1 hypothesized that the levels of PAs
would estimate the change of D with time.

Aim 2 hypothesized that changes in

polysomal mRNAs would estimate S with time.

Aim 3 hypothesized that these

experimental estimates of D and S could be fit by time course solutions of the theory
equations.
Given the germinal nature of the studies described here, we cannot state
unambiguously that the efforts were a success or failure. Perhaps the best indicator
along these lines are the trajectories depicted Figure 31 (Chapter 4). Although the
trajectories of our experimental data are not an ideal quantitative fit to the theory, the
general form of the trajectories is what one would expect based on the solutions of the
theory, particularly the MIM variants. This result provides us with cautious optimism that
the work described here is not wholly incorrect, and, in fact, may be on the right track.
We discuss several issues here including: (1) technical issues with estimating D
and S by PAs and polysome-bound mRNA, respectively, (2) technical issues with data
fitting, and (3) comments about the use of the MIM to fit the data. After these
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discussions, we give future directions ((1) The use of a mathematical framework to
understand biomedical results, (2) what would be entailed to actually confirm or refute
the theory once it is known how to measure D and S), and then offer concluding
remarks.
5.2 Technical Issues Estimating D and S
The first attempt to measure D and S reported here almost has a chicken or egg
quality. We cannot validate our measures of D and S unless we have independent
measures of D and S to compare them against. But this is the first attempt to measure
D and S, so there is nothing else to directly compare them against. However, it is not a
true chicken or egg problem because decades of detailed biomedical research has
demonstrated beyond a shadow of a doubt that after injury cells (1) contain molecules
they did not contain before the injury, which are damage products, and (2) the cells
express numerous stress responses intended to protect and repair the cell. Thus, the
concepts underlying D and S are sound. However, because this is the first attempt to
estimate their numerical values, there is no external validator and we can only discuss
our measures with respect to what is known of the detailed molecular biology.
Estimating D with PAs: The estimates of D (Figure 18) seem to be on
reasonable footing.

The final result shown in Figure 18 tallies with theoretical

considerations. That is, there should be a lot of D in CA1 that will die, and there should
be less D in CA3 that survives. This is indeed the result measured. The measure itself,
PAs, are known to be the end product of several upstream damage pathways including
loss of ATP, and altered ionic strength, pH, and redox status, all of which occur with
brain ischemia. Thus, PAs may well track the total amount of damage in the cells, even
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if the levels of PAs are only a specific percentage of this total damage. Tracking the
change in time was the important feature to match to theory solutions. The qualitative
difference between CA1 and CA3 is consistent with the theory solutions.
The CA1 and CA3 time courses were determined as carefully as possible, but we
note the error bars for CA1 PAs were substantially greater than CA3 PAs. This can be
accounted for by the theory. It is well-known that 10 min ischemia is close to the tipping
point amount of ischemia that kills CA1 neurons, but below that needed to kill CA3
neurons. It is possible some of the rats were just below and some just above the CA1
tipping point due to the vagaries of the surgical procedures. A small difference in core or
head temperature, or the rate at which blood was reinfused in the animals could make a
large difference near the tipping point. In other words, some CA1 entered into the study
might have been slightly below the tipping point, and would have survived. Such
animals would still make copious HSP70 and not be excluded from the study. If indeed
the CA1 PAs were a mixture of cells slightly below and slightly above the tipping point,
we would indeed expect large variances in our results, which is what was observed. On
the other hand, CA3 was well below its tipping point and provided a more homogeneous
sample where all CA3s entered into the study would survive, and we observed smaller
errors with CA3 PAs.
Estimating S with Polysome mRNAs: Clearly the same concern of proximity to
the tipping point pertains to our measurements of gene expression as it does with the
PA measurements. But there is another factor making polysome-bound mRNAs as less
than optimal indicators of S than PAs were of D. This was mentioned in the Introduction:
there are many gene-independent stress responses completely excluded from our
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method for estimating S. The gene independent stress responses include all of the preexisting machinery in cells which respond to injury. Some examples include stress
dependent signaling systems such as AMP kinase that responds to low levels of ATP,
or the stress activated protein kinases (SAPKs), members of the mitogen-activated
protein kinase family. In the Introduction was mentioned the taurine system activated in
response to hyperosmotic intracellular conditions. In general, these are transcriptionindependent, early response systems that respond immediately to cell injury. Over time,
gene dependent systems may come to dominate S due to the time it takes to activate
stress gene transcription and translation. These considerations suggest that our
estimates of S early in the time courses, at 30 min and 8 hr reperfusion, were probably
low compared to the real value. One means to deal with this would be to perform
phosphoproteomics in conjunction with the microarrays, under the expectation that
early, transcription-independent stress responses would involve substantial changes in
protein phosphorylation as stress signals are conveyed throughout the injured cells.
5.3 Data Fitting
The main strategy to determine if our measures of D and S were plausible was to
compare them to time course/trajectory solutions output by the theory equations and
determine if there was a best fit within a prescribed statistical significance, which was
2 in the present study. When viewing the SIM (Figure 32) and MIM (Figure 33) fits, it
must be kept in mind that points where the error bars overlapped the curve indeed fit
the curve to a 2 level of significance. However, for the SIM fits, there were points in
both CA1 and CA3 that did not fall on either the computed D or S time courses (Figure
32A and 24C). That all the data points did not fall on the line brings into question the
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quality of the fits. This could be due to either (1) choosing the wrong parameters, or (2)
the specific form of the theory equations being incorrect to fit the data.
A related point of great importance has to do with sampling. Each time course
extended over 72 hours, but each only consisted of 7 time points. This is an extremely
sparse sampling. However, the experiments involved large numbers of rats, and
(relatively) expensive microarray technology, and it was not possible within the budget
of the experiments to sample more points. Clearly, if more points were available, the
nature of the dynamical curve would be better revealed, and it would be easier to
formulate equations that produced matching forms.
There are automated methods for curve fitting nonlinear equations. One such
method our group has worked with is the Nelder-Mead simplex method, widely used in
physics and engineering to determine parameters for nonlinear differential equations.
We did not report these results in this Dissertation because the work is still in early
stages. One important lesson we have learned so far is that automatic fitting is not a
panacea but has its own limitations and pitfalls. The most important pitfall is that any
such method must be “seeded” with starting values of the parameters. The algorithm
starts from the seed parameters then systematically alters and retests the parameters,
while trying to minimize a least squares measure. The autonomous theory has five
parameters (cD, D, cS, S, and I). The SIM adds three additional parameters (v0, c1, c2)
for a total of 8. A 2-MIM doubles the number of parameters to 16, a 3-MIM triples them
to 24, and so on.
A common situation in using methods that require seeding in this fashion is the
possibility that the algorithm will diverge away from the desired solution.

This
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divergence occurs in an algorithm as apparently simple as Newton’s method used to
approximate roots of polynomials. The legend to Figure 39 explains four ways this can
occur when using Newton’s method to find the roots of a polynomial. Analogous means
of divergence occur when using automated methods to curve fit our data with the theory
equations. The possibility of divergence is compounded by the number of parameters.
This is why the curve fitting was begun with a “by eye” method. Here, one
manually enters parameters, and manually changes them, to try to produce curves that
fall on the data points. Then, in principle, these can serve as seed parameters for
automated fitting. Moving to the stage of automatic fitting seeded with “by eye”
determined parameters will be an ongoing part of the project for future students.

Figure 39: Newton method divergence. Some ways the Newton method can diverge
when seeking roots of polynomials. Clockwise starting from top left: An inflection point
can push the algorithm farther and farther from the root (where the graph crosses the x
axis). The algorism can get stuck in an oscillating cycle and never escape. The seed
value inadvertently causes a jump towards another, undesired solution. A horizontal
tangent can cause the algorithm to “shoot off” towards infinity.
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Another factor related to data fitting is that the experimental data was rescaled so
the maximum value of PA density or MDD was taken as 1. This was done to normalize
the PA and microarray data because we do not know the real concentration of PAs or
the real concentration of mRNA levels, at least with the REL x-fold and CN x-fold
datasets. By normalizing them, we could seek curve fits that lay in the plane from (0,1),
which is what was done above. However, the rescaling of the D and S estimates opens
up the wider issue of deriving a rescaled form of the SIM and MIM versions of the
theory. This is possible to do, and DeGracia, Huang, and Huang (2012) presented a
rescaled version of the autonomous model. However, it is not within the scope of this
Dissertation to undertake this task and is a subject for future students and future work.
Nonetheless, the main point related to fitting results shown here is that, technically, we
should have used such a rescaled version of the theory to be consistent with how the
data was handled.
To summarize, given that there was sparse sampling of the data and that the
fitting task is complicated by the number of parameters and the need to avoid
divergences, we can draw no firm conclusions from the fits shown in Figure 32 and
Figure 33. A conservative interpretation of the work displayed is that the theory is not
inconsistent with the data, that the data generally has the qualitative form the theory
leads us to expect, but the low sampling and other complexities means we cannot
definitively say that the fitting shows our measures of D and S are adequate estimates
of the theory variables.
5.3 Fitting with the MIM
The previous section describes the pitfalls of fitting that limit our interpretation of
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the data fits shown in Figure 32 and Figure 33. Being mindful of these limitations, we
nevertheless discuss now the MIM fits show in Figure 33.

These fits imply that

additional injuries are occurring endogenously in the post-ischemic brain. A striking
aspect of the raw data before fitting (Figure 26) is the impression of multiple curves
superimposed on each other. This impression is reinforced by the spline fits shown in
Figure 26. Strictly speaking, if we knew nothing of the system being studied, we should
ignore these impressions and be as objective as possible in finding a curve to fit the
data, as discussed in the previous section. However, there is over 40 years of brain
ischemia research and a tremendous amount of information is known about the detailed
cellular and molecular changes in the brain after ischemia, and specifically in the 2VO
rat model, a standard global ischemia model in the field for over 25 years.
The first study of microarrays of ischemic brain was presented in 1999. Since
that time a couple dozen studies have been reported. It is now understood that there
are “waves” of gene expression that occur during the reperfusion period and that these
“waves” correspond to the responses of neurons, glia, blood vessels, and the immune
system, each following their own intrinsic time courses, which in turn our conditioned by
the complex interaction of these cell types. The MaSigPro analysis (Figure 34 to Figure
37, and Table 10) recapitulates much that has already been established in the field.
Thus, the concept of multiple “waves” over time is already accepted in the field and
roughly corresponds to what a MIM system describes.
What is new is our ability to use the MIM as a theoretical lens through which to
view the many studies of waves of gene expression after brain ischemia. The following
are speculations using the theoretical lens provided by the MIM. Said succinctly, the
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MIM suggests that the tissue is injuring itself in a sublethal fashion as a way to respond
to the initial ischemia injury. It is as if there is a built in post-conditioning response.
Given all that is known of the biology, this is probably a combination of glial protective
responses and the immune system responses. Application of the MIM suggests that
these are working to effect a post-conditioning, sublethal insult designed to tip the
system overall from a pro-death to a pro-survival state. Additionally, we observed that
we got decent curve fits using a 2-MIM for CA1 and a 3-MIM for CA3. This indicates a
response is not occurring in CA1 that is occurring in CA3, and since CA3 survives, this
response might be critical for elevating S enough to allow CA3 cells to overcome the
ischemic damage. These comments must remain speculative and tempered by the
limitations of curve fitting discussed above. However, if true, or on the right track, this
would be a major insight on how tissue responds to injury.
5.4 The importance of parameter determination
The parameters obtained from the data fits are the most important part of this
project.

The cD and D parameters describe global brain ischemia. The cD and S

describe CA1 and CA3 as the cell types used in this experimental system. I is directly
proportional to the minutes of ischemia and is the control parameter since we wish to
see how the system behaves over a range of I vales. The other parameters n, v0, c1 and
c2 provide information about the kinetics of injury in CA1 and CA3. Specifically, v0 is the
multiplier of the rate of formation. c1 tells how the rate of formation varies with time. c2
tells the constant multiplier for the decay rate. All of these parameters give insight into
how the system dynamics behave. If these numbers could be determined in an
individual patient, this would, in principle, allow us to arrange a therapeutic strategy
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based on that patient’s specific condition.
Knowing the system parameters allows us to solve the theory for all possible
states of the system, since the theory allows us to calculate how D and S will behave at
any duration of ischemia. Once the system parameters can be validated, it can provide
a prognostic value that can predict the patient prognosis and condition on an each by
each basis120.
5.5 Therapeutic implication of the theory
Our work is driven by the clinical failure of therapy for brain ischemia. The most
important long-term question to arise from the data and parameters for CA1 and CA3
time courses was: How can we apply this theory and results to therapy? Currently,
many neuroprotectants are available to target against the specific damage mechanism
in brain ischemia including excitotoxicity, apoptosis, inflammation, oxidative stress,
blood-brain barrier disruption, apoptosis, or autophagy117. However, since most of all
these agents are failed in clinical trial91, our theory suggests we can reevaluate these
various drugs. The theory calculates a time course. But the system needs to be bistable
to have successful therapy. It is the bistable injury values of I where we can apply the
neuroprotection as calculated by bistability diagrams derived from specific input
parameters that need to be experimentally determined. The theory suggests that the
drugs may have failed either because it was not given at a bistable injury magnitude or
it was given at a time in the time course too late to salvage the brain cells. Another
question is how do we know the best time to give the drug or therapy? By having this
template of thinking, we can design experiments to determine which drugs are the best
on each time course of the ischemic progression. We can go back and test many of the
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drugs that have proven effective in the lab and determine over what ranges of I they are
effective, with the aim of clinical usage on that population of patients.
By having the bistability diagram and parameters that have been validated, there
will be a chance to develop a machine that can derive some of the parameters directly
from the patient condition and have pre-programmed other parameters experimentally
measured, like cD, cS, D, S.. This machine can calculate the ischemic progression in
the patient so that the doctor can decide whether the patient condition is effectively
treatable or not. Since brain ischemia patients admitted to the hospital with many
variability ischemic condition and previous health status or other concomitant illness
such as diabetes or hypertension, all patients present with different and nuanced
ischemic status. The treatment for brain ischemia patients need to be patient to patient
basis which is known as personalized medicine. Our theory is automatically one of
personalized medicine by allowing to calculate the specific trajectory and progression of
injury in each by each patient. The machine would not only predict the ischemia status
of the patient, but it would be able to calculate the best therapy that can be given to the
patient. This is why study of the MIM is so important. Therapy is a sublethal injury by
the MIM, and it can all be calculated. Determining what parameters to use is the key to
being successful to apply the model in the clinical circumstances.
5.6 Future Direction
The most important Future Direction for this project is to validate means to
measure D and S, and then apply these methods to test the theory equations. In
principle both steps could be accomplished by repeating the exact designs of Aims 1
and 2 at a series of ischemia durations, for example, at 2, 5, 7, 10, 12, 15, and 20 min of
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global brain ischemia. The present study produced one pair of D and S time courses for
each of CA1 and CA3 after 10 min global brain ischemia. The proposed study would
produce seven pairs of D and S time courses for each of CA1 and CA3. Such a design
would directly test the theory. The goal would be to find a set of parameters that fit all
seven pairs of time courses where the only parameter that varied was injury intensity, I.
If this could be done, it would confirm the theory and indirectly, confirm the measures of
D and S. However, as discussed above, the empirical measurement of S appears to
require refinement, especially at early reperfusion when gene independent stress
responses probably dominate the magnitude of S.
There are many smaller goals for future directions that need to be pursued, some
mentioned above. A next major step is to refine the curve fitting method by automatic
means to curve fit that are capable of dealing with the divergence problems is some
reasonable fashion. As stated, combining other omics technologies to estimate S, such
as different forms of proteomics, or metabolomics to measure small organic
metabolites, or lipidomics to measure damage and recover of lipid pools would help
refine the estimates of both D and S. Finally, continued work on the theory is required.
The SIM expressed in Eq. (17) is a nonautonomous differential equation. There is no
general theory of nonautonomous differential equations as there is a general theory of
solving linear ordinary differential equations. The SIM needs to be studied thoroughly
as was the original autonomous model (DeGracia et al 2012) to determine if the
solutions of the SIM can be easily classified in a fashion analogous to the autonomous
model.
Another future direction is to study the theory in a cell culture system, using a
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homogenous clonal population. This has the advantage of homogeneity as opposed to
the brain regions studied here that, although approximately 80-90% neuronal, still
consisted of heterogeneous tissue including blood vessels, white matter, and glia. The
disadvantage of the cell culture system is that it loses the direct clinical relevance of the
brain system used here. But the advantage is that is should provide a “cleaner” system
for the purpose of curve fitting and, because of the cell homogeneity, might only need to
fit the SIM and not the MIM.
5.7 Conclusions
It is concluded that the studies described here provide the tentative first steps
towards a new and unified understanding of the dynamics of acute cell injury. This
understanding is not grounded in the biological specifics of any one injured system, but
seeks to describe properties common to all injured systems and describe how injured
systems either recover or die as a function of time. The pitfalls and limitations of the
studies were given above and allow us to make only the most conservative conclusion
that the results do not outright contradict the theory, and that they provide tentative
evidence we are moving in the right direction.
It took about 40 years for the current paradigm of molecular biology to ascend to
dominance in biomedical research. This paradigm has led to a prodigious amount of
detailed biological description, but it hasn’t eradicated clinically-relevant acute injury
states as perhaps originally hoped. By applying methods that have worked essentially
flawlessly for 350 in physics, the perspective put forward in this Dissertation hopes to
open new doors where biomedical researchers can emulate the successes of the
physical sciences. Further, the view presented here depends critically on the detailed
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molecular biology view point and, we hope, represents the next stage in our evolution of
biomedical research, leading to a day when we can understand and control clinically
relevant injuries with the same precision engineers build cars, airplanes, and buildings.
When that time comes, medicine will serve an even greater role than it does today in
eradicating pain and suffering, and bringing health to humans around the world.
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APPENDIX A
IACUC Protocol Approval Letter
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APPENDIX B
HSP70 Validation of Ischemia Model
The following HSP70 Western blots are from cortical samples used to assess the
ischemia surgeries for samples used for isolation of protein aggregates. Samples
labeled with red font were excluded from the study.
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The following HSP70 Western blots are from cortical samples used to assess the
ischemia surgeries for samples used for isolation of total and polysomal RNA for
microarrays. Samples labeled with red font were excluded from the study.
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APPENDIX C
Microarray Class Comparisons between Groups
The tables of class comparisons between groups on the microarrays constitutes
several hundred pages of tables and are not practical to include in this document.
These tables are accessible through the internet at the following link:
http://www2.med.wayne.edu/degracialab/CCA/index.html
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This Dissertation is the first to estimate the variables D and S of the nonlinear
theory of acute cell injury in hippocampal regions CA1 and CA3 using a rat model of
global brain ischemia and reperfusion (I/R). D was estimated by quantifying protein
aggregates using ubiquitin Western blotting. S was estimated by quantifying changes in
polysomal mRNAs as measured by microarray chips. D and S time courses were
sampled at 0.5, 8, 16, 24, 48, and 72 hrs of reperfusion after 10 min brain ischemia.
CA1 dies and CA3 survives. The theory predicts D will be larger in CA1 and S in CA3.
Area under the curves of the D and S time courses showed this to be true. Trajectories
of D vs S qualitatively matched updated versions of the theory. However, quantitative
fits gave nonlinear correlation coefficients in the range 0.7-0.8. It was concluded that the
acquired data did not falsify the theory. However, inadequate sampling over the time
course, and the underestimation of S by failing to account for non-transcription
dependent stress responses prevented strong quantitative fits between the measured
estimates of D and S and theoretical time courses.
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